   
A Phase 1 Dose Escalation Trial Evaluating the Safety 
and Pharmacokinetic Profile of BIO 300 Oral Powder in 
Healthy Volunteers  
 
 
 
 Short title:  Phase 1 BIO 300 Oral Powder  
 
   
Protocol Number: CL01 06-01 
National Clinical Trial (NCT) Identified Number:  [STUDY_ID_REMOVED] 
Principal Investigator:  Amy R. Eastenson, MD  
IND Sponsor : Humanetics Corporation  
Version Number:  v3 .0 
07 June 2021 
 
    
 
 
 
       
 
  
 
  
Phase 1 BIO 300 Oral Powder – v3.0 07 June  2021 ii Table of Contents  
STATEMENT OF COMPLIANCE  ............................................................................................................................. 1  
1 PROTOCOL SUMMARY  ............................................................................................................................... 1  
1.1 Synopsis  ................................................................................................................................................ 1  
1.2 Schema  ................................................................................................................................................. 4  
1.3 Schedule of Activities (SoA)  ............................................................................................................... 6  
2 INTRODUCTION  ............................................................................................................................................ 8  
2.1 Background and Study Rationale  ...................................................................................................... 8  
2.2 Risk/Benefit Assessment  .................................................................................................................... 8  
2.2.1  Known Potential Risks  ..................................................................................................... 8  
2.2.2  Known Potential Benefits  .............................................................................................. 10 
2.2.3  Assessment of Potential Risks and Benefits  .............................................................. 10 
3 OBJECTIVES AND ENDPOINTS  .............................................................................................................. 10 
4 STUDY DESIGN  ........................................................................................................................................... 11 
4.1 Overall Design  .................................................................................................................................... 11 
4.2 Scientific Rationale for Study Design .............................................................................................. 11 
4.3 Justification for Dose  ......................................................................................................................... 11 
4.4 End of Study Definition  ..................................................................................................................... 11 
5 STUD Y POPULATION  ................................................................................................................................ 12 
5.1 Inclusion Criteria  ................................................................................................................................ 12 
5.2 Exclusion Criteria  ............................................................................................................................... 12 
5.3 Lifestyle Considerations  .................................................................................................................... 14 
5.4 Screen Failures  .................................................................................................................................. 15 
5.5 Strategies for Recruitment and Retention  ...................................................................................... 15 
6 STUDY INTERVENTION  ............................................................................................................................ 15 
6.1 Study Intervention(s) Administration  ............................................................................................... 15 
6.1.1  Study Intervention Description  ..................................................................................... 15 
6.1.2  Dosing and Administration  ............................................................................................ 15 
6.2 Preparation/Handling/Storage/Accountability  ................................................................................ 16 
6.2.1  Acquisition and accountability  ...................................................................................... 16 
6.2.2  Formulation, Appearance, Packaging, and Labeling  ................................................ 16 
6.2.3  Product Storage and Stability  ....................................................................................... 17 
6.2.4  Preparation  ...................................................................................................................... 17 
6.3 Measures to Minimize Bias: Randomization and Blinding ........................................................... 18 
6.4 Study Intervention Compliance ........................................................................................................ 18 
6.5 Concomitant Therapy  ........................................................................................................................ 18 
6.5.1  Permitted Surpportive Therapy  .................................................................................... 18 
6.5.2  Non- Permitted Surpportive Therapy  ........................................................................... 18 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  .................................................................................................................... 18 
7.1 STOPPING CRITERIA FOR DISCONTINUATION OF  THE STUDY INTERVENTION  ......... 18 
7.2 Discontinuation of Study Intervention  ............................................................................................. 19 
7.3 Participant Discontinuation/Withdrawal from the Study  ............................................................... 19 
7.4 Lost to Follow -Up ............................................................................................................................... 19 
7.5 Dose Escalation Criteria  ................................................................................................................... 20 
8 STUDY ASSESSMENTS AND PROCEDURES  ..................................................................................... 20 
8.1 Criteria for evaluation  ........................................................................................................................ 20 
  
Phase 1 BIO 300 Oral Powder – v3.0 07 June  2021 iii 8.2 Safety and Other Assessments  ....................................................................................................... 20 
8.3 Blood Sampling for Pharmacokinetics, Safety and Biomarkers  ................................................. 22 
8.3.1  Single ascending dose subject blood volume requirements  ................................... 24 
8.3.2  Multiple single dose subject blood volume requirements  ......................................... 24 
8.4 Adverse Events and Serious Adverse Events  ............................................................................... 25 
8.4.1  Definition of Adverse Events (AE)  ............................................................................... 25 
8.4.2  Definition of Serious Adverse Events (SAE)  .............................................................. 25 
8.4.3  Classification of an Adverse Event  .............................................................................. 25 
8.4.4  Time Period and Frequency for Event Assessment and Follow -Up ....................... 26 
8.4.5  Adverse Event Reporting  .............................................................................................. 27 
8.4.6  Serious Adverse Event Reporting  ............................................................................... 27 
8.4.7  Events of Special Interest  ............................................................................................. 27 
8.4.8  Reporting of Pregnancy  ................................................................................................ 27 
8.5 Unanticipated Problems  .................................................................................................................... 28 
8.5.1  Definition of Unanticipated Problems (UP)  ................................................................. 28 
8.5.2  Unanticipated Problem Reporting  ................................................................................ 28 
9 STATISTICAL CONSIDERATIONS  .......................................................................................................... 29 
9.1 Statistical Hypotheses  ....................................................................................................................... 29 
9.2 Sample Size Determination  .............................................................................................................. 29 
9.3 Populations for Analyses  .................................................................................................................. 29 
9.4 Statistical Analyses ............................................................................................................................ 29 
9.4.1  General Approach  .......................................................................................................... 29 
9.4.2  Analysis of the Primary Efficacy Endpoint(s)  ............................................................. 30 
9.4.3  Analysis of the Secondary Endpoint(s)  ....................................................................... 30 
9.4.4  Safety Analyses  .............................................................................................................. 30 
9.4.5  Baseline Descriptive Statistics  ..................................................................................... 31 
9.4.6  Planned Interim Analyses  ............................................................................................. 31 
9.4.7  Sub-Group Analyses  ..................................................................................................... 31 
9.4.8  Tabulation of Individual participant Data  .................................................................... 31 
9.4.9  Exploratory Analyses  ..................................................................................................... 31 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  .............................. 31 
10.1 Regulatory, Ethical, and Study Oversight Considerations  ........................................................... 31 
10.1.1  Informed Consent Process  ........................................................................................... 31 
10.1.2  Study Discontinuation and Closure  ............................................................................. 32 
10.1.3  Confidentiality and Privacy  ........................................................................................... 32 
10.1.4  Future Use of Stored Specimens and Data  ............................................................... 33 
10.1.5  Key Roles and Study Governance  .............................................................................. 33 
10.1.6  Safety Oversight  ............................................................................................................. 34 
10.1.7  Clinical Monitoring  .......................................................................................................... 34 
10.1.8  Quality Assurance and Quality Control  ....................................................................... 34 
10.1.9  Data Handling and Record Keeping  ............................................................................ 35 
10.1.10  Protocol Deviations  ........................................................................................................ 35 
10.1.11  Publication and Data Sharing Policy  ........................................................................... 36 
10.1.12  Conflict of Interest Policy  .............................................................................................. 36 
10.2 Abbreviations  ...................................................................................................................................... 36 
10.3 Protocol Amendment History  ........................................................................................................... 38 
11 REFERENCES  ............................................................................................................................................. 40 
  
Phase 1 BIO 300 Oral Powder – v3.0 07 June  2021 iv 12 Appendices  .................................................................................................................................................... 40 
Appendix 1: Soy Rich Foods  ............................................................................................................................... 40 
 
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
1 STATEMENT OF COMPLIANCE  
The trial will be carried out in accordance with International Conference on Harmonisation Good Clinical 
Practice (ICH GCP) and the following:  
•United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part46, 21 CFR Part  50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812)
National Institutes of Health (NIH) -funded investigators and clinical trial site staff who are responsible 
for the conduct, management, or oversight of NIH- funded clinical trials  have completed  Human Subjects 
Protection and ICH GCP Training.  
The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the Institutional Review Board ( IRB) for review and approval.  Approval of both the 
protocol and the consent form must be obtained before any participant is enrolled.  Any amendment to the protocol will require review and approval by the IRB before the changes are implemented to the study.  In addition, a ll changes to the consent form will be IRB- approved; a determination will be made 
regarding whether  a new consent needs to be obtained from participants who provided consent, using a 
previously approved consent form . 
1 PROTOCOL SUMMARY  
1.1 SYNOPSIS  
Title:  A Phase 1 Dose Escalation Trial Evaluating the Safety and Pharmacokinetic 
Profile of BIO 300 Oral Powder in Healthy Volunteers   
Study Description : Single Ascending Dose:  
Open -label, single -dose escalation in healthy volunteers.  Each cohort will 
enroll 8 subjects of which 2 will be  backups  (1M/1F) , so that  at least 6 
subjects (3M/3F) complet e the protocol procedures. The pertinent safety 
data will be reviewed for each cohort before the next dose level cohort is started.  Subjects will follow a diet low in soy isoflavones for 7 days before and 7 days after treatment and will fast at least 8 h before dosing. The test 
article will be administered on day 1 and the initial dose will be one BIO 
300 Oral Powder sachet , 500  mg genist ein. Subsequent doses will be 2x 
the previous cohort. The fourth, and final cohort, dose level will be TBD 
based on the safety and pharmacokinetic (PK) results from the previous 3 cohorts.  Subjects will remain in the clinic 12 h ours  after dosing for 
observatio ns and blood sample collection for clinical lab assessment, PK, 
and pharmacodynamics (PD).  Subjects will remain fasted for 4 hours after the test article administration. Subjects will be provided a standardized low soy meal after the 4 -hour blood draw and  after the 8- hour blood 
draw.  Subjects will return to the clinic on day 2, 3 and 8 after dosing for 
blood sampling and/or observations as detailed in the schedule of events. 
Subjects may not miss any clinic visits. At the conclusion of the study, data 
will be analyzed from all cohorts to determine safety and PK.  PD samples will be stored until the completion of all p hase 1 studies, and then sent for 
RNA sequencing and data analysis.  
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
2 Multiple Single Dose:  
Open -label, single dose given daily for 6 days in healthy volunteers. A 
single cohort  will enroll 14 subjects ( 7M/7F) of which 4 will be  backups  
(2M/2F) , so that  at least 8 subjects  (4M/4F)  complet e the protocol 
procedures. Subjects will follow a diet low in soy isoflavones for 7 days 
before  treatment, during the 6 days of treatment  and 7 days after 
treatment. Subjects  will fast at least 8 h before the first dose, 3rd dose and 
the 6th dose . The test article will be administered starting on day 1 and 
the dose used in this study will be determined based on safety and PK analysis from the single ascending dose study. Subjects will be administered test article daily during their schedule clinic visits.  S ubjects 
will remain in the clinic 4 h ours  after the first dose and 12 hours after the 
6th dose for observations and blood sample collection for clinical lab assessment, PK and PD.  Subjects will remain fasted for 4 hours after the 
test article administrati on on days 1 and 6. On the  6th day, subjects will be 
provided a standardized low soy meal after the 4- hour  blood draw and 
after the 8- hour blood draw.  Blood sampling and/or observations will be 
performed on dosing days 1 -6 as described in the schedule of events. 
Subjects will return to the clinic on days 7, 8 and 13 after initial dosing for 
blood sampling and/or observations as detailed in the schedule of events. Subjects may not miss any clinic visits.  At the conclusion of the study, data 
will be analyzed to determine safety  and PK, and data will be analyzed 
from all cohorts to determine PD.  
Objectives:  Primary Objectives:  
•Determine  the overall adverse event and PK profiles of single
ascending doses of BIO 300 Oral Powder in healthy volunteers
•Determine  the overall adverse event and PK profile of multiple
doses of BIO 300 Oral Powder in healthy volunteers
Secondary Objectives:  
•Determine  the effects of single and multiple doses of BIO 300 Oral
Powder on blood -based biomarkers
•Use a combination of the PK and PD profiles from the single andmultiple doses of BIO 300 Oral powder to identify the putative BIO300 Oral Powder human efficacious dose
Endpoint s: Primary  
Evaluate the safety and pharmacokinetics of BIO 300 Oral Powder  in 
Health y Volunteers  
Secondary  
Characterize  the expression of blood -based biomarkers   
Study Population:  • 6 subjects/cohort ( 3M/3F) will be recruited for the single
ascending dose study, and at least 6 (3M/3F) subjects/cohort will
complete all aspects of the study.  2 additional subjects  (1M/1F) ,
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
3 will be screened , consented  and avail able as backups for each 
cohor t. 
• 10 (5 M/5F) subj ects will be recruited for the multiple single dose
study, and at least 8 (4M/4F) subjects will complete all aspects of
the study.  4 additional subjects  (2M/2F)  will be screened ,
consented  and available as backups .
• In total, at least 32 healthy volunteer s who will complete all
aspects of the trial.
Phase:  1  
Description of 
Sites /Facilities  Enrolling 
Participants : Nucleus Network (formally Prism Clinical Research ) 
1000 Westgate Drive, #149  
Saint Paul, MN 55114  
Description of Study  
Intervention: BIO 300 Oral Powder  will be provided by Humanetics Corporation, 
Minneapolis, Minnesota.  
 
 The inactive ingredients  
include povidone K 12 and sucralose powder.  The vials are labeled with 
clinical study information including the lot number, storage instructions to 
store at controlled room temperature 15 -30°C (59 -86°F) and the 
statement “CAUTION: New Drug, limited by Federal law to investigational 
use.”   
Study Duration:  Approximately 8 months  
Participa nt Duration:  The duration of study participation will be 35 days for Cohorts 1 – 4 (28 -
day screening period; Dosing on day 1; final follow -up visit on Day 8).  
The duration of study participation will be 41 days for Cohort 5 (28 -day 
screening period; Dosing on days 1 - 6; final follow -up visit on day 13)  

Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
4 1.2 SCHEMA  

Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
5 

Phase 1 BIO 300 Oral Powder 
Protocol CL0106-01 
1.3 SCHEDULE OF ACTIVITIES (SOA) 
Schedule of Events and Assessments 
Visit Number· 
Day 
hlfom1ed Consent 
Medical Histo1y 
Concomitant Medication 
Contraception Check 
Vital Sicms1 
Calculation ofBMI 
Phvsical Exam2 
Dmg Screen/Alcohol Testine. 
Pre=ancv test3 
Hepatitis and HIV testing 
CBC with differential4 
PT/INR,PTT 
Semm chemistries and fasting lipid panels 
Urinalvsis6 
ECG7 
Low isoflavone dietary counseling 
Administer BIO 300 Oral Powder 
PK 
PD 
Adverse Event Monitoring 
Notes Single Ascending Dose Cohorts 
1 2 3 4 
-28 to -81 2 3 
X 
X 
X X X X 
X X X X 
X xsX X 
X 
X X 
X X 
X X 
X 
X X 
X X 
X X 
X 
X x9 X X 
X X X X 
X 
xioxux12 
x14xis
X X X 5 1 
8 -28 to
-8
X 
X 
X X 
X X 
X X 
X 
X X 
X 
X X 
X 
X X 
X X 
X X 
X X 
X X 
X 
X Version 3.0 
07 June 2021 
Multiple Single Dose Cohort 
2 3 4 5-6 7 
1 2 3 4-5 6 
X X X X X 
X X X X X 
xnX X X xs
X X 
X 
X 
X X 
X X 
X X 
X 
x9 X X X 
X X X X 
X X X X X 
x13xio
x14x16
X X X X X 8 9 10 
7 8 13 
X X X 
X X X 
X X X 
X 
X 
X 
X 
X 
X 
X 
xux12 
xis
X X X 
1.Vital signs include height, weight, BMI, resting pulse, blood pressure, respiratory rate, and temperature. Subjects should be rested semi-recumbent for at least 5 min prior to collection.
2. Physical exams will assess the HEENT, lymphatic, cardiovascular, pulmonary , gastrointestinal, musculoskeletal, and neurological systems, and anything else deemed necessary by
the Investigator.
3. Pregnancy test may be performed on urine or serum
4. CBC to include white blood cell count with differential, platelet count, red blood cell count, hemoglobin , and hematocrit
5.Serum cliemistries to include total protein, albUlllin, sodium, potassium, chloride, bicarbonate, glucose, BUN, creatinine, alkaline phosphatase, ALT, AST, uric acid, LDH, total and 
direct bilirubin, phosphorous, calcium, magnesium, amylase, lipase, total cholesterol, triglycerides, HDL. Subjects should fast at least 8 h prior to collection and blood will be drawn
prior to test article administration.
6. Urinalysis to include pH, specific gravity, dipstick determinations of protein, glucose, ketones, blood and bilirubin and reflex 
microscopic exan1 (reflex only if any qualitative
measurements or appearance return abnormal)
7. ECGs to be oerformed in triolicate with 5-minute inteivals. Subiects should be rested suoine for at least 5 minutes orior to collection.
6 
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
7 8. Vital signs to be obtained within 1 hour prior to administration of BIO 300 Oral Powder and then approximately 30 minutes, 1, 2, 4, 6, 8, and 12 h following administration of BIO
300 Oral Powder
9. ECGs to be obtained within 1 h prior to BIO 300 Oral Powder administration and then approximately 1, 2, and 4 h following BIO 300 Oral Powder administration
10. Samples for PK assessment to be obtained just prior to BIO 300 Oral Powder administration and then 30 minutes, 1, 2, 4, 6, 8,  and 12 h following BIO 300 Oral Powder  administration . 
The time of the blood draw will be ±10 minutes of the nominal time.
11. Samples for PK assessment to be obtained 24 + 2 h following administration of BIO 300 Oral Powder
12. Samples for PK assessment to be obtained 48 + 4 h following administratio n of BIO 300 Oral Powder
13. Samples for PK assessment to be obtained just prior to administration of BIO 300 Oral Powder and then 30 minutes, 1, 2,  and 4 h following BIO 300 Oral Powder administration. 
The time of the blood draw will be ±10 minutes of the nom inal time.
14. Samples for PD assessment to be obtained - 2 to 0 h before BIO 300 Oral Powder administration, and 1, 2, and 4 h following BIO 300 Oral Powder administration. The time of the
blood draw will be ±10 minutes of the nominal time.
15. Samples for PD asse ssment to be obtained 24 + 2 h following administration of BIO 300 Oral Powder
16. Samples for P D assessment to be - 2 to 0 h before BIO 300 Oral Powder administration, and 4, 8, and 12 h following BIO 300 Oral Powder administration. The time of the blood draw 
will be ±10 minutes of the nominal time.
17. Vital signs to be obtained within 1 hour prior to administration of BIO 300 Oral Powder and then approximately 30 minutes, 1, 2, and 4 h following administration of BIO 300 Oral
Powder
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
8 2 INTRODUCTION  
2.1 BACKGROUND AND STUDY RATIONALE  
The active ingredient in BIO 300 Oral Powder is g enistein , a selective agonist of estrogen receptor beta 
(ERβ ). ERβ activation promotes DNA repair, cell cycle regulation, and importantly, anti- inflammatory 
effects. This pleiotropic mechanism can partly be explain ed by ERβ’s ability to repress expression  and 
activation  of nuclear factor kappa light -chain -enhancer of activated B cells (NF -κB), which is a master 
regulator that controls transcription of genes involv ed in the immune response and cell survival 1-3. NF-
κB is activated in response to radiation, infection or other immune stimuli, and in turn promotes 
expr ession of pro -inflammatory cytokines [reviewed in  4]. 
Humanetics is developing BIO 300 for multiple clinical indication s related to DNA damage and 
inflammation.  The primary indication for BIO 300 Oral Powder is as a prophylactic medical 
countermeasure to increase survival in individuals exposed to myelosuppressive doses of ionizing radiation.  
BIO 300 has been studied in a previous clinical trial (NCT 02567799 ) as an aqueous oral nanosuspension  
(BIO 300 Oral Suspension) .  BIO 300 Oral Powder has been developed to facilitate a solid dosage form of 
BIO 300.  The pharmacokinetics of  BIO 300 Oral Powder are not fully known in humans, and the safety 
and maximum tolerated d ose of this formulation is unk nown .  This phase 1 study is intended to 
methodically explore both safety and PK of this formulation in healthy human volunteers.  In addition, 
blood -based  biomarkers will be examined as part of an effort to develop a human do se conversion 
strategy under the FDA Animal Rule. 
Refer to the Investigator’s Brochure (IB) for more detail.  
2.2 RISK/BENEFIT ASSESSMENT  
2.2.1  KNOWN  POTENTIAL RISKS  
All study participants  in th is clinical trial will receive identical care and health assessments.  This will be 
explained in detail at the time of consent to participate. Patient alternatives include the choice not to participate in this study, a decision that may mean no specific follow -up care .  
 
 
 
 
 
 
 
 
 
 
 
 
 

Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
9 Subject
s wit
h documented soy allergies should carefully consider taking BIO 300. Because BIO 300 is 
manufactured with synthetic genistein the risk of a soy -based allergic reaction is minimal. Although 
teratology studies were negative, it is not known if BIO 300 will cause harm when administered to 
pregnant women. If a patient becomes pregnant while taking BIO 300, the patient should be informed of 
potential hazards to the unborn fetus. For these reasons mothers who are nursing their children should be informed of potential hazards of taking BIO 300.  
 
 
 
  
The
 following list summarizes the potential physical risks associated with participation in the proposed 
clinical study  based upon known adverse events in previous clinical studies of BIO 300  at the proposed 
dose and dosing duration : 
Less Likely  
•Fatigue
•Constipation
•Diarrhea
•Dyspepsia
•Flatulence
•Anorexia
•Dysgeusia
•Increase in serum amylase
•Increase is serum lipase
•Decrease in the number of red blood cells
•Increase in blood pressure
•Lowering of the heart rate
•Increase in breathing rate
•Pain such as headaches, aches in muscles and joints and abdominal pain
•Change in appetite

Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
12 Section 9 and prepare a final study report that will be submitted to the Investigational New Drug 
Application  (IND). 
5 STUDY POPULATION  
5.1 INCLUSION CRITERIA  
In order to be eligible to participate in this study, an individual must meet all of the following criteria:  
1)Healthy adult non -smokers, 18 -64 years old.
2)BMI 18 -32 kg/m2
3)No inges
tion of prescription or over-the -counter medications (including dietary and herbal
supplements) for 7 days prior to first dose of study drug and no planned use during study
participation.  Acetaminophen of up to 3 g/day and ibuprofen up to 1 g/day wil l be allowed at
discretion of the Investigator.
4)At the discretion of the Investigator, b lood routine, liver and kidney functions are within the
controllable range .
a.Adequate hepatic function as evidenced by ALT, AST or LDH < 1.25 X ULN and bilirubin <
1.5X ULN for the reference lab .
b.Adequate renal function as evidenced by a serum creatinine ≤ 1.5 X ULN for thereference laboratory OR a calculated creatinine clearance o f ≥ 60 mL/min by the
Cockcroft -Gault Equation .
c.Adequate hematopoietic function as evidenced by white blood cells ≥ 3 x10
9 / L and
platelets ≥ 100x109 / L.
5)Female subjects of childbearing potential must have a negative pregnancy test within 72 hoursof the s tart of treatment.
6)Subjects must agree to abstain from heterosexual intercourse or use a reliable method of
contraception  for 7 days after their last dose.  Subjects using hormonal  contraception are
required to utilize condom/spermicide + additional barrier method for 7 days after their last
dose .
7)Ability to read and provide written informed consent .
8)Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory
tests, dietary restrictions,  and other study procedures.
9)No clinically significant abnormalities identified by medical history, physical examination, vitalsigns, ECG, and clinical laboratory tests in the opinion of the Investigator.
5.2 EXCLUS ION CRITERIA  
An individual who meets any of the following criteria will be excluded from participation in this study:  
1)Any prior use of the study test article.
2)Any clinically significant weight loss any time in prior 4 weeks at discretion of Investigator based
on medical history interview.
3)Subjects with any of the following are not eligible;
a.Previous history of QTc prolongation resulting from “known -risk” medication s
(www.Crediblemeds. org) that required discontinuation of that medication;
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
13 b.Congenital long QT syndrome, or 1st degree relative with unexplained sudden death
under 40 years of age;
c.Presence of left bundle branch bloc k (LBBB);
d.QTc with Fridericia’s correction  (QTcF) that is unmeasurable, or ≥ 480 msec on screening
ECG. The average QTcF from the screening ECG (completed in triplicate) must be <  480
msec in order for the subject to be eligible for the study .
4)Subjects m ust not have had a clinically significant cardiac event such as myocardial infarction
(within 6 months prior to the first dose of the study treatment); uncontrolled/symptomaticcongestive heart failure (New York Heart Association (NYHA) classification of heart disease, ClassIII or IV, see Appendix 3) within 6 months before entry; or the presence of any otheruncontrolled cardiovascular conditions [unstable hypertension at discretion of Investigator orarrhythmia, unstable angina pectoris, or severe valvular heart disease, etc.] that, in the opinionof the Investigator, increases the risk of ventricular arrhythmia.
5)Subjects with a history of arrhythmia (multifocal premature ventricular contractions (PVCs),bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which issymptomatic or requires treatment (CTCAE Grade 3) or asymptomatic sustained ventriculartachycardia are not eligible.  Subjects with atrial fibrillation with well- controlled ventricular rate
are eligible  at the discr etion of the Investigator .
6)Psychiatric conditions, social situations or substance abuse that precludes the ability of thesubject to cooperate with the requirements of the trial and protocol therapy at Investigatordiscretion.
7)Inability to refrain from alc ohol consumption for 48 hours prior to day 1 and for the duration of
the study.  Illicit drugs, including THC, must be avoided from screen through the duration of the
study.
8)Grade 2 or higher peripheral neuropathy.
9)Positive results for Hep B surface antigen, Hep C antibody, or HIV 1/2 antibody at screening visit .
10)Clinically significant  immunodeficiency disorder  in the opinion of the Investigator.
11)Pregnancy  or women  of childbearing  potential  and men  who  are sexually  active  and not
willing/able  to use medically  acceptable  forms  of contraception.
12)Women who are breastfeeding are not eligible for this study.
13)Subjects that are vegan, vegetarian or consume a soy -rich diet.
14)Any history of systemic infection requiring hospitalization, systemic antibiotics, or as judged
clinically significant by the investigator in the 3 months prior to day 1.
15)Any condition possibly affecting drug absorption (e .g., prior bariatric surgery, gastrectomy,
intestinal resection).  Participants who have underg one appendectomy or cholecystectomy are
allowed so long as the surgery occurred more than 6 months prior to day 1.
16)Treatment with another investigational drug within 30 days or 5 half- lives (whichever is longer)
proceeding Day 1.
17)Positive drug screen or alcoho l test at screen and day 1 predose.
18)Blood donation of approximately 1 pint (500 ml) or more within 60 days of day 1; plasmadonations within 14 days of day 1.  Subjects must agree not to donate blood or plasma for theduration of the study and for 30 days following end of study procedures.
19)Inability to swallow powdered medication followed with water.
20)History of sensitivity to heparin or heparin -induced thrombocytopenia .
21)Considered by the Investigator to be unsuitable to participate in the study for any other reason .
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
14 5.3 LIFESTYLE CONSIDERATIONS  
Participants will be counseled to adhere to a low isoflavone diet , such as those listed in Appendix 1 , 
during the dosing and PK/PD assessment period.  It is important for study participants  to maintain a low 
isoflavone diet (e.g., low soy -diet) in order  to accurately quantify study drug pharmacokinetics and drug 
exposure.  
Contraception : 
1)Women who are not able to get pregnant are not required to use birth control. To be
considered not able to get pregnant, you must be
a)postmenopausal for at least 12 months confirmed by hormone testing ; or
b)surgically sterile
-hysterectomy (surgical removal of uterus)
-bilateral tubal ligation (tubes “tied”)
-removal of both ovaries and/or fallopian tubes
2)Wome n
 who are  able to get pregnant must
a)have a negative urine pregnancy test at screening and on admission to CRU ; and
b)must be using, and agree to continue using, an effective method of contraception for at least4 weeks prior to first study drug administration until 7 days after the last dose of study drug.
Effective methods of contraception include the following:  
1)Total abstinence from sexual intercourse with a partner that may result in pregnancy
2)Sexual intercourse with a partner who has had a vasectomy
3)Non -Hormonal Intrauterine device
4)Double barrier contraception, i.e., condom and diaphragm, or condom or diaphragm withspermicidal gel or foam.
5)Women using hormonal contraception below must agree to use a barrier or other effective
method of contraception during the study
a)Combined (estrogen and progestogen containing) hormonal contraception-oral
-intravaginal
-transdermal
b)Progestogen -only hormonal contraception
-oral
-injectable
-implantable
Women must not donate ova (eggs) during the study and for at least 30 days after the last dose of study 
drug.  
Male subjects who have not had a vasectomy and/or subjects who have had a vasectomy but have not 
had 2 post -surgery negative tests for sperm whose partners are not on a highly effective method of 
contraception (hormonal contraception is sufficient for female partners) must agree to use an acceptable method of contraception from time of first dose of study drug until 30 days after the last dose of the study 
drug, and must not donate sperm during the study and for at least 30 days after the last dose of study drug.  
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
15 5.4 SCREEN FAILURES  
Screen failures are defined as participants who consent to participate in the clinical trial but are not 
subsequently entered in the study  due to their inability to meet inclusion or exclusion criteria or their 
decision to not consent to enroll ment . A minimal set of screen failure information is required to ensure 
transparent reporting of screen failure participants , to meet the Consolidated Standards of Reporting 
Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. 
Minimal information includes demography, screen failure details, eligibility criteria, and any serious adverse event (SAE).  
5.5 STRATEGIES FOR RECRUITMENT AND RETENTION  
Recruitment of subjects  will be performed by the clinical site who maintains a robust database of 
health y volunteers.  The site will outreach to potential participants to encourage  screening.  
For optimal recruitment and retention, subject  contact and convenience will be prioritized. Examples 
include providing effective subject  information on the study, providing face -to-face meetings for 
discussing the study and questions, and ensuring the  study design places no significant burden to being 
involved in the research study.  
Subjects  will be in contact with the study through  clinical visits.  Subject  outreach will occur to 
encourage continued compliance and participation in clinic visits during the repeat dose  study period.  
6 STUDY INTERVENTION  
The study intervention being investigated under this protocol is BIO 300 Oral Powder , an amorphous 
solid dispersion of synthetic genistein.  
6.1 STUDY INTERVENTION (S) ADMINISTRATION  
6.1.1  STUDY INTERVENTION  DESCRIPTION  
BIO 300 Oral Powder  will be provided by Humanetics Corporation, Minneapolis, Minnesota.  BIO 300 
Oral Powder is an amorphous solid dispersion of genistein.  It is packaged in single use foil sachets  
containing 500  mg genistein .  It is a free -flowing pale orange to slightly tan powder.  
6.1.2  DOSING AND ADMINISTRATION  
Single Ascending Dose Cohorts:  
Cohort 1 dose : one BIO 300 Oral Powder sachet, 500 mg genistein  
Cohort 2 dose : two BIO 300 Oral Powder sachet s, 1000 mg genistein  (2X the dose of Cohort 1 in the 
absence of dose -limiting toxicity [DLT])  
Cohort 3 dose : four BIO 300 Oral Powder sachets, 2000 mg genistein (2X the dose of Cohort 2 in the 
absence of DLT)  
Cohort 4 dose : TBD based on the observed PK  and AE profiles  in the first 3 dose cohorts  
All single dose cohorts will be administered the drug at the clinic under the supervision of the study 
personnel . Subjects will follow a diet low in soy isoflavones for 7 days before and 7 days after treatment 
and will fast at least 8 h before dosing. Subjects will remain fasted for 4 hours after the test article 
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
16 administration. Subjects will remain in the clinic 12 hours after dosing. Subjects will be provided a 
standardized low soy meal after the 4 -hour blood draw and after the 8 -hour blood draw. The purpose of 
fasting is to standardize the effect of food on PK and PD markers.  
Multiple Single Dose Cohort:  
The c ohort 5 dose will be dosed daily for 6 consecutive days at the highest dose or the maximum 
tolerated dose from  the Single Ascending Dose cohorts.  Subjects will consume the test article each day 
within + /- 2 hours of time when the first dose was administered and not within 1 hour before or after 
eating .  The Day 6 dose will be administered during clinic visit 7 so that PK and PD blood draws can be 
timed after the dose.  
Drinking of room temperature water only, ( up to 240 mL ) will be encouraged following administration of 
each BIO 300 Oral Powder  sachet .  
Subjects will follow a diet low in soy isoflavones for 7 days before  treatment, during the 6 days of 
treatment  and 7 days after treatment . Subjects  will fast at least 8 h be fore the first dose, 3rd dose and 
the 6 th dose . Subjects will remain in the clinic 4 h after the first dose and 12 hours after the 6th dose . 
Subjects will remain fasted for 4 hours after the test article administration on days 1 and 6. On the 6th day, subjects will be provided a standardized low soy meal after the 4 -hour blood draw and after the 8-
hour blood draw.  The purpose of fasting is to  standardize the effect of food on PK and PD markers.  
6.2 PREPARATION/H ANDLING/ STORAGE/ ACCOUNTABILITY  
6.2.1  ACQUISITION  AND ACCOUNTABILITY  
BIO 300 Oral Powder  will be supplied to the investigational site pharmacy in foil sachets , each containing 
500 mg of genistein.   Sachets will be bulk packed in car dboard boxes  and will be labeled as a new drug 
for investigational use only.  All dosing cohorts will be administered whole sachets for dosing (e.g., 1 
sachet for the 500 mg cohort).  
Study drug used during the trial wil l be on an ICH compliant stability study  with appropriate retest 
intervals.  Any expired or out -of-spec drug product will be quarantined by the pharmacy  and will be 
disposed upon full drug accountability monitoring and instruction by the S ponsor.    
6.2.2  FORMULATION, APPEARANCE, PACKAGING, AND LABELING  
Description and Composition  
The drug product, BIO 300 Oral Powder, is an amorphous solid dispersion (ASD)  
 
The 
composition of BIO 300 Oral Powder is s hown in Table 6.2.2.1 .  
Table 6.2.2.1 BIO 300 Oral Powder quantitative composition 
Component  Function Reference to 
Quality Standard Amount (mg/g)  

Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
17 Genistein (Bonistein®)  Active Ingredient 
(API)  In-house   
Polyvinylpyrrolidone K12  Carrier/Stabilizer USP  
Sucralose Sweetener  NF  
The ASD/s
ucralose mixture is filled into 1.5”x2.5” high barrier, multi-layer low -density polyethylene 
(LDPE)/foil, individual dosing sachets. The drug product contact surface of the sachet is comprised of linear 
low-density polyethylene (LLDPE).  
  
The drug product is labelled for investigational use only.  
6.2.3  PRODUCT STORAGE AND STABILITY  
BIO 300 Oral Powder  is to be stored at 15 -30°C, at ambient relative humidity  by the study site 
pharmacy .  The sachets  should be stored in their original packaging until dispensed.   Protection from 
light is not required. The sachets will be stored at the study facility and will be dispensed according to 
the study protocol.  An extra supply of the BIO 300 Oral Powder study drug will be available in the event 
additional sachets  are needed once the study is underway.  
6.2.4  PREPARATION  
The steps for preparing and dispensing BIO 300 Oral  Powder  are as follows:  
1)Prepare the subject identifier label to each sachet.
2)Holding the sachet from the top  (end with V grooves), gently swing back and forth to force all
powder to the bottom of sachet .
3)Tear the top off the sachet being careful not to spill any powder.
4)Pour entire contents of sachet into mouth .
5)Immediately consume up to 8 oz. of water.
6)Inspect sachet to ensure all powder was dispensed.  If not, take any residual powder
immediately.
7)Follow steps 3 and 4 if more than 1 sachet is required.  You may space the time between sachetsbut consume all within a 5 minute  period.

Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
18 6.3 MEASURES TO MINIM IZE BIAS: RANDOMIZATION  AND BLINDING  
This is an open label, non -randomized phase 1 trial . 
6.4 STUDY INTERVENTION  COMPLIANCE  
Adherence to the protocol will be assessed by documenting study visits.  Study intervention compliance 
will be assessed by accounting for the  number of returned empty sachets .  
6.5 CONCOMITANT THERAPY  
For this protocol, a prescription medication is defined as a medication that can be prescribed only by a 
properly authorized/licensed clinician. M edications to be reported in the Case Report Form ( CRF) are 
concomitant prescription medications, over -the-counter medications,  and supplements . 
6.5.1  PERMITTED SURPPORTIVE THERAPY  
All supportive therapy for optimal medical care will be given during the study period at the discretion of the subject’s  attending physician(s) within the parameters of the protocol and documented on the  site’s 
source documents as concomitant medication.  
6.5.2  NON-PERMITTED SURPPORTIVE THERAPY  
Though no data have shown that any concomitant medications will interfere with BIO 300 Oral Powder , 
it is advisable that s ubjects  do not take any other medication(s) 1 hour before or after a dose of BIO 300 
Oral Powder . Concomitant medications will be collected for all subjects from the screening visit through 
the end of the study .  
The following drugs are not permitted during the study protoco l: 
Anti-pulmonary fibrosis  therap eutics , (e.g.,  imatinib, nintedanib, pirfenidone, penicillamine, colchicine, 
and tumor necrosis factor alpha blocker), anti -cytokine release syndrome therapeutics ( e.g.,  anakinra, 
sarilumab, siltuximab, tocilizumab and/or lenzilumab) , biologics used to treat asthma ( e.g., omalizumab, 
mepolizumab, reslizumab, benralizumab and dupilumab) , and all systemic  corticosteroids . 
If a subject  receives any of the listed non -permitted supportive therapies, this will constitute as a major 
protocol deviation .  
7 STUDY INTERVENTION  DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/ WITHDRAWAL  
7.1 STOPPING CRITERIA FOR DISCONTINUATION OF THE STUDY INTERVENTION 
Discontinuation of a subject and early stopping of the study intervention  will be based on the following 
unacceptable adverse events (AEs) and must be attributable to the investigational drug BIO 300 Oral Powder  (i.e., possibly, probably or d efinitely related to the study drug) to constitute a Dose-Limiting 
Toxicity (DLT).   
•Non-hematologic toxicities of Grade 3 or higher, with the following exceptions:
oanorexia
ofatigue
oinfection without neutropenia
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
19 oGrade  3 AST/ALT elevations ≤ 7 days
oGrade 3 or 4 electrolyte abnormalities that are corrected to Grade 2 or less in less than
48 hours.
•Occurrence of a VTE (DVT or pulmonary embolism) .
7.2 DISCONTINUATION OF STUDY INTERVENTION  
Discontinuation from BIO 300 Oral Powder  does not mean discontinuation from the study, and the 
remaining study procedures should be completed as indicated by the study protocol.  If a clinically 
significant finding is identified (including, but not limited to changes from baseline) after en rollment, the 
Principal Investigator or qualified designee will determine if any change in participant management is needed. Any new clinically relevant finding will be reported as an adverse event (AE).  
7.3 PARTICIPANT  DISCONTINUATION /WITHDRAWAL  FROM THE S TUD Y 
Subjects  are free to withdraw from participation in the study at any time upon request.  The Principal 
Investigator may discontinue  or withdraw a subject from  the study for the following reasons : 
•Pregnancy  (see Section 8.4.8 ). Women of childbearing potential must perform a pregnancy test
in case of delayed menstruation and stop treatment immediately in case of positive result.
•Significant study intervention non -compliance .
•Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness that, in the
opinion of the Principal Investigator, indicates that  continued participation in the study is  not in
the best interest of the participant .
•If the participant  meets  an exclusion criterion (either newly developed or not previously
recognized) that precludes further study participation .
•If the participant w ithdraw s their  informed consent .
The reason for participant discontinuation or withdrawal from the study will be r ecorded on the Case 
Report Form ( CRF). Subjects who sign the informed consent form and are randomized but do not receive 
the study intervention may be replaced.   
7.4 LOST TO F OLLOW-UP 
For both the Single Ascending Dose and the Multiple Single Dose studies  a subject  will be considered lost 
to follow -up if he or she fails  to return for a single visit  and is unable to be contacted by the study site  
staff.  
The following actions must be taken if a participant fails to return to the clinic for a required study visit:  
•The site will attempt to contact the participant and reschedule the missed visit as soon as
possible that same day  and counsel the participant on the importance of maintaining the
assigned visit schedule and ascertain if the participant wishes to and/or should continue in the
study.
•If the missed visit consists of timed blood draws for PK  and PD , that subject will be immediately
cons idered lost to follow up and may be replaced.
•Should the subject  be unreachable, he or she will be considered to have withdrawn from the
study with a primary reason o f lost to follow -up.
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
20 For both the Single Ascending Dose and Multiple Single Dose studies , subjects that are lost to follow up 
may be replaced.  F or the S ingle Ascending Dose study, and at least 6 (3M/3F) subjects/cohort will 
complete all aspects of the study.  For the Multiple Single Dose study at least 8 (4M/4F) subjects will 
complete all as pects of the study.  
7.5 DOSE ESCALATION CRITERIA  
A Safety M o
nitoring Committee (SMC) consisting of a Humanetics representative, the Medical Monitor 
and Principal Investigator, or their recognized delegates will review all available data. The determination 
for escalation to the next Cohort will require, at a minimum, a review of all safety data of 6 subjects in the previous SAD Cohort through at least Day 3.   Decisions to proceed with dose escalations, adding 
additional subjects to the current Cohort, and possible dose adjustments will be made following this review with the Medical Monitor and Principal Investigator agreeing with the decision.  Whether 
additional information such as PK or PD data may be needed before a decision to escalate can also be determined by the SMC. The primary responsibility of the SMC is to regularly monitor the overall safety 
of patients enrolled in the study, while protecting the scientific integrity of the study data.  Dose 
escalation  criteria will be the following:
 
•Dose esc
alation may occur if no more than 2 subjects in a 6- subject cohort experiences a dose -limiting
toxicity (DLT, as defined below).
•If 3 DLTs occur (3/ 6 subjects), an additional 2 subjects will be treated with the same dose.
•If no additional DLTs occur (3/ 8 subjects), dose escalation may proceed.
•The study sponsor will temporarily cease enrollment for evaluation if in any given cohort 4/ 8 subjects
exper ience DLTs attributable to BIO 300 Oral Powder as the MTD (maximum tolerated dose) will have
been exceeded and no further dose escalation will occur.
DLT is any grade 3 or grade 4 adverse event listed in the draft FDA document entitled “ Toxicity Grading 
Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials .” 
8 STUDY ASSESSMENTS AND PROCEDURES  
8.1 CRITERIA FOR EVALUATION  
Safety:  
The safety profile of BIO 300 Oral Powder will be based on the results of CBC with differential, coagulation 
parameters, serum chemistries, urinalysis, ECGs, and vital signs the reporting of adverse events.  
Pharmacokinetics:  
Blood samples will be collected at multiple timepoints after BIO 300 Oral Powder administration and processed for serum isolation. Serum concentrations of genistein aglycone will be measured from PK parameters (C
max, T max, clearance, AUC (0-24;0- 48;0- INF), volume of distribution, T 1/2 and drug accumulation 
index) which will be calculated using standard procedures and statistical analyses.  
Pharmacodynamics:  
Blood samples will be collected at multiple timepoints in PAXgene tubes after BIO 300 Oral Powder 
administration.  It will be subject ed to RNA sequencing to explore biomarkers which may be predictive of 
BIO 300 Oral Powder effectiveness.  
8.2 SAFETY AND OTHER ASSESSMENTS  
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
21 Physical Exam  – Exam ination of  the participant’s  cardiovascular, HEENT, lymphatic , pulmonary , 
gastrointestinal, musculoskeletal,  and neurological systems.  
Vital Signs  – Vital signs will record the patient’s height, weight and BMI. They will also measure heart 
rate, blood pressure  (systolic and diastolic), respiratory rate, and  body temperature . 
Electrocardiogram  – ECGs occur  during the screening visit , on visit 2 (1 hr before, 1hr after, 2 hrs after 
and 4 hrs after BIO 300 Oral Powder dose), and visits 3 -5 for the SAD phase . ECGs will occur during the 
screening visit, visit 2 (1 hr before, 1hr after, 2 hrs after and 4 hrs after BIO 300 Oral Powder dose) , visits 
3-4, visit 7 and visit 10 for the multiple single dose phase.  ECGs  will be digitally  read locally  at the study
site. ECGs  will be  completed in triplicate and the average will be used to determine if the study subject
has an abnormal reading.
QTc Interval Prolongation  – Fridericia- corrected QTc (QT cF) interval from all subject s in both the SAD 
and the multiple single dose studies  will be used to evaluate QTc F interval prolongation. QTcF 
prolongation will be determined by evaluating ECG at baseline (pre -dose) and at multiple time points 
around the predicted C max of BIO 300 Oral Powder ( ECG timepoints listed above ). QTcF intervals will be 
reported for each dosing cohort as a mean and standard deviation. The upper limit for QTc F interval 
prolongation will be >480 ms or absolute QTc F change from baseline of >30 ms with a 95% confidence 
interval. The relationship between drug exposure and mean QTc F interval change will be evaluated in 
the SAD study using both C max and AUC. Any adverse events that may signal a potential proarrhythmic 
effect will be carefully monitored (e.g., Torsade de pointes, sudden death, ventricular tachycardia, 
seizures, etc.). 
Complete Blood Count  – Blood sampling for the laboratory parameters will be performed during the 
screening and BIO 300 Oral Powder treatment period according to the study schedule ( Section 1.3). A 
complete blood count with differential will evaluate  hemoglobin, hematocrit, re d blood cells (RBCs), 
white blood cells (WBCs), neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelet 
count . 
Serum Chemistry  and Fasting Lipid Panel  – Blood serum will be used to evaluate the blood chemistry 
parameters . Serum chemistries to include total protein, albumin, sodium, potassium, chloride, 
bicarbonate, glucose, BUN, creatinine, alkaline phosphatase, ALT, AST, uric acid, LDH, total and direct 
bilirubin, phosphorous, calcium, magnesium, amylase, lipase, total cholesterol, triglycerides, HDL. Subjects will fast at least 8 h prior to blood collection for serum chemistries . 
PTT/INR  – Prothrombin Time (PTT)  is a test that evaluates a subject’s  ability to appropriately form blood 
clots.  The International Normalized Ratio (INR) is a calculation based on results of the PTT that is used to 
monitor individuals who are being treated with the blood -thinning medication . 
Pregnancy Test  – Tests will occur at screening, day 1 and during the final visit  (SAD, day 8, visit 5; 
Multiple Single Dose, day 13, visit 10) . Tests will use urine or serum for determination of β-HCG.  
Viral Testing  – Test will occur at screening for both studies. Tests will utilize blood  for analysis of the 
Hepatitis B surface antigen, Hepatitis C antibody , and HIV1 and HIV2 antibody.  
Urinalysis  – To include pH, specific gravity, dipstick determinations of protein, glucose, ketones and 
bilirubin , blood  and reflex microscopic exam (reflex only if any qualitative measurements or appearance  
return abnormal)  
Concomitant Medications  – A record of c oncomitant medications will be collected for all subjects from 
the screening visit through BIO 300  Oral Powder treatment and the one-week follow-up phase.  
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
22 Assessment of Adverse Events  – All adverse events (AEs) will be collected from the time the subject 
takes their first dose of BIO 300 Oral Powder until 7 days after their last dose of BIO 300 Oral Powder.  
AEs will be documented and submitted to the Sponsor. Any serious AEs (SAEs) will be documented and 
reported to the Sponsor within 24 hours of awareness (see Section 8.3). 
Blood -Based Biomarkers  – Whole  blood will be collected for biomarker analysis. Blood will be collected 
pre-dose,  at several time points around the predicted C max of BIO 300 Oral Powder. The collected 
samples will be subject to RNA extraction and next- generation RNA sequencing on the  Illumina HiSeq  
platform with paired -end sequencing.  
8.3 BLOOD SAMPLING FOR PHARMACOKINETICS, SAFETY AND B IOMARKERS  
Blood will be collected from all subjects to monitor BIO 300 Oral Powder pharmacokinetics, safety, and 
biomarkers. At each visit where blood sampling occurs, whole blood and serum may  be collected for 
pharmacokinetics, complete blood counts (CBC) with differential, serum chemistry , clotting (PT /INR, 
PTT) and RNA extraction . A summary of blood draws for safety and biomarkers can be found in Section 
1.3 Schedule of Activities. Below is an overview of the details of the blood collection summarized by visit.  
For blood draw s, whole blood will be collected in one 3 cc lavender top blood collection tubes  for CBC 
analysis  and two PAXgene blood RNA tubes  for RNA isolation . The PAXgene tubes  will be stored at -7 0°C 
until they are shipped to a Sponsor -designated laboratory  for RNA extraction and processing. Blood will 
also be collected in one 3.5 mL SST collection tube for serum isolation  to be used for serum chemistry  
and 1x 3cc red top  blood collection tube for serum isolation to be used for BIO 300  Oral Powder PK 
analysis . Blood used for serum will be allowed to clot 20 -30 minutes and then centrifuged at room 
temperature for 10 -15 minutes. Collected serum will be frozen at -70 °C. All blood and serum will be 
shipped to the sponsor -designated bioanalytical lab for analysis. Additionally, at screening, blood will be 
collected into another 3.5 mL SST collection tube, and a 3 mL EDTA collection tube to be used for viral 
testing . Specific blood draw volume requirements for the procedures listed below are detailed in 
Section 8.3.1  and Section 8.3.2 . 
Single Ascending Dose  
Visit 1 (Screening)  
At the screening visit, blood will be collected to acquire  the subject’s baseline  blood count s and serum 
chemistries , and for viral testing. If a pregnancy test is required for the subject, either a serum or urine 
test will be done at this time. These test results will assist in determining the subject’s ability to be included in the trial (see Section  5.1 Inclusion Criteria ). 
Visit 2 (Day 1 ) 
All subjects  will have their blood collected for serum as described above. Serum samples will be 
collected for pharmacokinetic s just prior to and  following administration of a single dose of BIO 300 Oral 
Powder at 30 minutes, 1,  2, 4, 6, 8, and 12 hours.  The time of the blood draw will be ±10 minutes of the 
nominal time. Subjects will be given a standardized low -soy meal  after the 4 h blood draw an d 2 h after 
the 6 h blood draw . Whole blood will be collected as described above for RNA isolation prior to a single 
dose BIO 300 Oral Powder administration, and at 1, 2 and 4 hours after administratio n. 

Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
23 Visit 3 (Day 2 ) 
All subjects will have blood serum collected for PK 24 ± 2 hrs after BIO 300 Oral Powder dosing.  Whole 
blood will also be collected for RNA isolation 24 ± 2 hrs after BIO 300 Oral Powder dosing.  
Visit 4 (Day 3 ) 
All subjects will have a whole blood and serum collected for CBC, PT/INR, PTT, 4 8 ± 4 hrs  PK and serum 
chemistry  as described above.  
Visit 5 (Day 8) 
All subjects will have a whole blood and serum collected for CBC, PT/INR, PTT  and serum chemistry as 
described above.  
Multiple Single Dose  
Visit 1 (Screening)  
At the screening visit, blood will be collected to acquire the subject’s baseline blood counts , serum 
chemistries , PT/INR, PPT , and viral testing . If a pregnancy test is required for the subject, either a serum 
or urine test will be done at this time. These test results will assist in determining the subject’s ability to 
be included in the trial (see Section 5.1 Inclusion Criteria ). 
Visit 2 (Day 1)  
All subjects will have their blood collected for serum as described above. Serum samples will be collected for pharmacokinetics just prior to and following administration of a single dose of BIO 300 Oral Powder at 30 minutes, 1, 2 and 4 hours . The time of  the blood draw will be ±10 minutes of the nominal 
time.  Whole blood will be collected as described above for RNA extraction  prior to a single dose BIO 300 
Oral Powder administration, and at 1, 2 and 4 hours after administration.  
Visit 4 (Day 3) 
All subjects will have a whole blood and serum collected for CBC , serum chemistry, and PT/INR, PPT  as 
described above.  
Visit 5 and 6 (Days 4 and 5)  
All volunteers will have their vital signs performed and will be administer a single dose of BIO 300 Oral Powder at the research unit.  
Visit 7 (Day 6) 
All subjects will have their blood collected for serum as described above. Serum samples will be collected for pharmacokinetics just prior to and following administration of a single dose of BIO 300 Oral Powder at 30 minutes, 1,  2, 4, 6, 8, and 12 hours. The time of the blood draw will be ±10 minutes of the 
nominal time.  Subjects will be given a standardized low -soy meal after the 4 hr blood draw and 2 hours 
after the 6 -hour blood draw. Serum will also be  used for serum chemistry analysis . Whole blood will be 
collected as described above for RNA extraction  prior to a single dose BIO 300 Oral Powder 
administration, and at 4 , 8 and 12 hours after administration. Whole blood will also be collected  for CBC 
analysis.  
Visit 8 (Day 7) 
All subjects will have blood serum collected for PK 24 ± 2 hrs after BIO 300 Oral Powder dosing. Whole 
blood will also be collected for RNA extraction 24 ± 2 hrs after BIO 300 Oral Powder dosing.  
Visit 9 (Day 8)  
All subjects will have blood serum collected for PK 48 ± 4 hrs after BIO 300 Oral Powder dosing. 
Phase 1 BIO 300 Oral Powder 
Protocol CL0106-01 
Visit 10 (Day 13) Version 3.0 
07 June 2021 
All subjects will have a whole blood and serum collected for CBC, serum chemistry, and PT/INR, PPT as 
described above. 
j s.3.1 SINGLE ASCENDING DOSE SUBJECT BLOOD VOLUME REQUIREMENTS
Blood volume (mL) required 
Visit Numbe1· 1 2 3 4 s 
·2Day 1 Day2 Day3 Days TOTAL ...." 
CBC 
(Lavender top 3 3 3 9 
whole blood) 
Serum Chemistry 3.5 3.5 3.5 10.5 (SST) 
PT/INRPTT 2.7 2.7 2.7 8.1 ,ssn 
Viral Testing 6.5 6.5 (SST and EDTA) 
BIO 300 Oral 24 Powder PK (3cc x 8 draws) 3 3 30 
<Red top serum) 
BIO 300 Oral 20 Powder PD (5mLx4 5 25 (RNA) 
(PAX2ene tube) draws) 
Waste associated 
with use of 8 8 
heoarin lock 
Subtotals 9.2 52 8 12.2 9.2 
STIJDY TOTAL 97.1 
j s.3.2 MULTIPLE SINGLE DOSE SUBJECT BLOOD VOLUME REQUIREMENTS
Blood volume (mL) required 
Visit Number 1 2 3 4 s 6 7 8 9 
·2Dayl Day Day Day Day Day6 Day Day ....2 3 4 s 7 8 " 
CBC 
(Lavender top whole 3 3 3 
blood) 
Serum Chemistry 3.5 3.5 3.5 SST) 
PT/INRPTT 2.7 2.7 2.7 (SST) 
Viral Testing 6.5 (SST and EDTA) 10 
Day TOTAL 13 
3 12 
3.5 14 
2.7 10.8 
6.5 
24 
Phase 1 BIO 300 Oral Powder 
Protocol CL0106-01 Version 3.0 
07 June 2021 
BIO 300 Oral Powder 15 
PK (3cc x 5
ffied top sernm) draws) 
BIO 300 Oral Powder 20 
PD(RNA) (5mLx 
(PAX2ene tube) 4 draws) 
Waste associated with 5 use of heparin lock 
Subtotals 11 40 11 
STUDYTOTAL 
8.4 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS 
18.4.1 DEFINITION OF ADVERSE EVENTS (AE) 24 
(3cc x 8 3 3 45 
draws) 
20 
(5mLx 5 45 
4draws) 
8 13 
63 8 3 11 
146.3 
An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug 
in humans, whether or not considered drug related. Therefore, an AE can be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not considered related to the medicinal 
(investigational) product (attribution of unrelated, unlikely, possible, probable, or definite) (ICH, E2A, 
E6). 
18.4.2 DEFINITION OF SER1ous ADVERSE EVENTS (SAE) 
SAEs that fit any one of the criteria in the SAE definition below must be reported to the Sponsor 
within 24 hours of awareness of the event. 
An adverse event (AE) or suspected adverse reaction is considered "serious" if, in the view of either the 
Principal Investigator or Sponsor, it results in any of the following outcomes: 
•Death;
•A life-threatening adverse event;
•Inpatient hospitalization or prolongation of existing hospitalization;
•A persistent or significant incapacity or substantial disruption of the ability to conduct normal
life functions;
•A congenita l anomaly/birth defect.
Important medical events that may not result in death, be life-threatening, or require hospitalization 
may be considered serious when, based upon appropriate medical judgment, they may jeopard ize the 
participant and may require medical or surgical intervention to prevent one of the outcomes listed in 
this definition. 
18.4.3 CLASSIFICATION OF AN ADVERSE EVENT 
8.4.3.1 SEVERITY OF EVENT 
For adverse events (AEs), guidelines based on the FDA Guidance for Industry Toxicity Grading Scale for 
Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials will be used to 
describe severity. The guidance provides a toxicity grading scale (grade 1, mild; grade 2, moderate; 
grade 3, severe; grade 4, potentially life threatening) for clinical and laboratory abnormalities. For AE 
25 
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
26 terminology, the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be used , 
and AE system organ classification will follow the Medical Dictatory for Regulatory Activities ( MedDRA).  
8.4.3.2  RELATIONSHIP TO STUDY INTERVENTION  
All adverse events ( AEs) must have their relationship to study intervention assessed by the clinician who 
examines and evaluates the participant  based on temporal relationship and his/her clinical judgment.  
The degree of certainty about causality will be graded using the categories below. 
•Definite  – There is clear evidence to suggest a causal relationship, and other possible
contributing factors can be ruled out. The clinical event, including an abnormal laboratory test
result, occurs in a plausible time relationship to study intervention  administration and cannot be
explained by concurrent disease or other drugs or chemicals. The event must bepharmacologically or phenomenologically definitive.
•Probabl e – There is evidence to suggest a causal relationship, and the influence of other factors
is unlikely. The clinical event, including an abnormal laboratory test result, occurs within areasonable time after  administration of the study intervention , is unlikely to be attributed to
concurrent disease or other drugs or chemicals, and f ollows a clinically reasonable response on
withdrawal.
•Possibl e – There is some evidence to suggest a causal relationship (e.g., the event occurred
within a reasonable time after administration of the study intervention ). However, other factors
may have contributed to the event (e.g., the participant ’s clinical conditi on, other concomitant
events). Although an AE  may rate only as “possibly related” soon after discovery, it can be
flagged as requiring more information and later be upgraded to “probably related” or “definitelyrelated”, as appropriate.
•Unlikely – A clinical event, including an abnormal laboratory test result, whose temporal
relationship to study intervention  administration makes a causal relationship improbable (e.g.,
the event did not occur within a reasonable time after administration of the study intervention )
and in which other drugs or chemicals or underlying disease provides plausible explanations(e.g., the participant ’s clinical condition, other concomitant treatments).
•Unrelated  – The AE is completely independent of study  intervention  administratio n, and/or
evidence exists that the event is definitely related to another etiology.
8.4.3.3  EXPECTEDNESS  
The Principal Investigator will be responsible for determining whether an adverse event ( AE) is expected 
or unexpected.  An AE  will be considered unexpected if the nature, severity, or frequency of the event is 
not consistent with the risk information previously described for the study intervention .  The final 
determination of expectedness will be determined by the Medical Monito r in consultation with the 
Principal Investigator. 
8.4.4  TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
The occurrence of an adverse event (AE ) or serious adverse event (SAE ) may come to the attention of 
study personnel during study visits and inte rviews of a study participant  presenting for medical care, or 
upon review by a study monitor.  
All AEs including local and systemic reactions not meeting the criteria for SAE s will be captured on the 
appropriate  case report form  (CRF). Information to be collected includes event description, time of 
onset, clinician’s assessment of severity, relationship to study product (assessed only by those with the 
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
27 training and authority to make a diagnosis), and time of resolution/stabilization of the event. All AEs 
occurring while on study must be documented appropriately regardless of relationship. All AEs will be 
followed to adequate resolution.  
Any medical condition that is present at the time that the participant  is screened , or after they are  
screened, but before they are administered the first dose of study drug,  will be considered as baseline 
and not reported as an AE. However, if the study participant’s condition  deteriorates at any time during 
the study, it will be recorded as an AE.  
Chan ges in the severity of an AE will be documented to allow an assessment of the duration of the event 
at each level of severity  to be performed. A Es characterized as intermittent require documentation of 
onset and duration of each episode.  
Delegated study personnel  will record AE s with start dates occurring any time after the first dose of 
study intervention  is administered  through the end of the study . SAEs will be recorded with start dates 
occurring any time after informed consent is obtained through the end of the study. At each study visit, the investigator will inquire about the occurrence of AE/SAEs since the last visit.  Events will be followed 
for outcome information until resolution or stabilization.  Documentation of the serious event will be 
reported  on the Serious Adverse Event CRF and submitted to the Sponsor  within 24 hours of awareness.  
8.4.5  ADVERSE EVENT REPORTING  
The notification process to the study Sponsor  of all safety data begins with the completion and 
submission of the appropriate CRFs or in the case of an  initial serious event reporting, by phone. 
Investigators are required to report promptly to the Sponsor  any adverse events that may reasonably be 
regarded as caused by, or probably caused by, the drug. If the Adverse Event (AE) meets the Serious 
Adverse Event (SAE) criteria, the investigator is required to report the event to the Sponsor  within 24 
hours of awareness.    
8.4.6  SERIOUS ADVERSE EVENT REPORTING  
The Sponsor  will notify the FDA , all participating investigators in a written IND safety report of any 
adverse experience associated with the use of the drug that is both serious and unexpected and any finding from tests in laboratory animals that suggests a significant risk for human subjects. The Sponsor  
will submit an IND safety report to the FDA and all participating investigators no later than 15 c alendar 
days after the Sponsor  determines that the suspected adverse reaction or other information qualifies for 
reporting.  Unexpected fatal or life- threatening suspected adverse reactions will be reported to the FDA 
no later than 7 calendar days after the  Sponsor ’s initial receipt of the information. If the FDA requests 
any additional data or information, the Sponsor  will submit it to FDA as soon as  possible, but no  later 
than 15 calendar days after receiving the request.  
8.4.7  EVENTS OF SPECIAL INTEREST  
Subjects that experience  any cardiovascular-related events , overdose on the study intervention,  have 
any clinically significant laboratory test abnormalities , or become COVID -19 positive  should be  reported 
to the study Sponsor . 
8.4.8  REPORTING OF PREGNANCY  
Should a participant become pregnant during the study, the Principal  Investigator  will report this event 
to the stu dy Sponsor  and will create a plan to stop the study  intervention  as soon  as possible. The 
Principal Investigator will communicate with the physician managing the pregnancy and the subject and 
pregnancy will be followed to term.  
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
28 8.5 UNANTICIPATED PROBLEMS  
8.5.1  DEFINIT ION OF U NANTICIPATED PROBLEMS (UP) 
The Office for Human Research Protections ( OHRP ) considers unanticipated problems involving risks to 
participant s or others to include, in general, any incident, experience, or outcome that meets all  the 
following criteria:  
• U nexpec
ted in terms of nature, severity, or frequency given (a) the research procedures that are
described in the protocol -related documents, s uch as the IRB -approved research protocol and
informed consent document; and (b) the characteristics of the participant  population being
studied;
• Related or possibly related to participation in the research (“possibly related” means there is a
reasonable p ossibility that the incident, experience, or outcome may have been caused by the
procedures involved in the research); and
• S uggests that the research places participant s or others at a greater risk of harm (including
physical, psychological, economic, or s ocial harm) than was previously known or recognized.
8.5.2   UNANTICIPATED PROBLEM REPORTING 
The Principal Investigator will report unanticipated problems ( UPs) to the reviewing Institutional Review 
Board ( IRB) and t o the Sponsor . The UP report will include the following information:  
•Protocol identifying information: protocol title and number, PI’s name, and the IRB project
number;
• A detailed description of the event, incident, experience, or outcome;
• A n explanation of the basis for determining that the event, incident, experience, or outcome
represents an UP ;
• A description of any changes to the protocol or other corrective actions that have been taken or
are proposed in response to the UP .
To satisfy the requirement for prompt reporting, UP s will be reported using the following timeline:  
• UP s that are serious adverse events ( SAEs) will be reported to the IRB and to the study Sponso r
in accordance with the sites policies and procedure s and within 24 hours  of the investigator
becoming aware of the event.
•Any other UP  will be reported to the IRB  and to the study Sponsor  within one week  of the
investigator becoming aware of the problem.
All UPs should be reported to appropriate institutional officials (as required by an institution’s
written reporting procedures), the supporting agency head (or designee), and the Office for
Human Resear ch Protections ( OHRP ) within 7 business days  of the IRB’s receipt of the report of
the problem from the investigator.
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
29 9 STATISTICAL CONSIDERATIONS 
9.1 STATISTICAL HYPOTHESES  
Data analysis of the primary  endpoints will be based on measurements  of genistein aglycone (free 
genistein) serum concentrations (0 -48 h) . They will also be based on safety assessments  which include 
blood counts, serum chemistries, urinalysis, ECGs, vital signs, and PTT/INR at the timepoints listed in the 
SoA, Section 1.3 .  “Baseline” will refer to measurements taken during the screening visit.  If no “baseline” 
data exists from a parameter, then changes in the parameter time regression will be compared.  
As this i s a single dose  escalation  and multiple single dose  trial evaluating the safety and  pharmacokinetic 
profile of BIO 300 Oral Powder, the statistical  hypotheses for the safety measurements is that there will 
be no change in safety measurements during BIO 300 Oral Powder dosing, and 7 days after the last BIO 
300 Oral Powder dose.  
For the secondary endpoint , the statistical hypothesis is that there will be a significant change in the level 
of expression of one or more genes  that is attributable to BIO 300 Oral Powder dose.   
9.2 SAMPLE SIZE  DETERMINATION  
The single ascending dose study consists of 4 cohorts , each with at least 6 subjects completing all 
aspects of the study , split evenly to include at least 3 fe males and 3 males. As such, 12  
 females and 12 males will participate for a total of 24 subjects. The multiple  single dose study will 
include at least 8  subjects  completing all aspects of the study , split evenly to include at least 4 females 
and 4 males . This is a sufficient number of subjects in each study to characterize the PK and PD of BIO 
300 Oral Powder and  to identify DLTs.   
9.3 POPULATIONS FOR A NALYSES  
All participants will be analyzed. The ITT dataset is the primary dataset for analysis. As a guide, analyses 
may include, but are  not limited to, any or all of the following:  
•Intention -to-Treat (ITT) Analysis Dataset: all participants
•Safety Analysis Dataset : participants who took at least one dose of BIO 300  Oral Powder
9.4 STATISTICAL ANALYSES  
9.4.1  GENERAL APPROACH  
An independent statistician using standard statistical techniques will determine statistically significant 
differences in the trial measurement data . Statistical significance will be set at the nominal level of 
p<0.05. Plasma concentrations (genistein aglycone; free genistein) will be measured (AUC, C max, Tmax, 
T1/2) and plasma kinetic rate will be calculated using standard procedures and statistical analyses (e.g., 
AUC using the linear trapezoidal formula and T 1/2 using linear regression). Data will be summarized by 
descriptive statistics (mean/medians and standard errors/confidence intervals for continuous response variables and distribution tables or histograms for discrete response variables).  
Baseline ch
aracteristics will be compared using matched -pair t -tests. The computed change from 
baseline will be calculated for all measured variables and expressed as the mean change from base line 
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
30 and accompanying standard deviation (SD) of the change from baseline. Repeated measures ANOVA 
tests will be used to compare changes in scores for each variable between each treatment group. Matched pair t -tests will be  used to compare the change scores within each treatment group. All data 
analyses will be conducted on the subjects who completed the study treatment periods and statistical 
significance will be set at p<0.05.  
9.4.2  ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S)  
Blood counts, serum chemistry , urinalysis , ECGs, vital signs,  and PTT/INR  for the study cohorts will be 
reported as a mean ± SD at each of the timepoints listed in the SoA, Section 1.3 . An analysis of 
covariance (ANCOVA) to compare the cohorts  after adjusting for "baseline" (the adjustment covariate) 
will be completed.  Analysis will be performed  in individual  subjects  to identity changes in safety 
measurements relative to baseline, and between cohorts at the timepoints listed in the SoA, Secti on 1.3  
to identify any potential dose -response relationships.   
9.4.3  ANALYSIS OF THE SECONDARY ENDPOINT(S)  
For the secondary endpoint of RNA sequencing, statistical analysis will be used to detect differential expressed gene s (DEGs) . Analysis will be performed  in individual  subjects  to identity DEGs  relative to 
baseline, and between cohorts at the timepoints listed in the SoA, Section 1.3  to identify dose -response 
relationships.  
RNA samples will be sequenced using an Illumina HiSeq approach that will produce 20 -30 million paired 
end reads per sample. Raw reads will be mapped to the human  genome. Reads will be normalized as 
fragments per kilobase million (FPKM) and used to identify DEGs for biomarker evaluation . 
9.4.4  SAFETY ANALYSES  
All adverse ev ents  (AEs), including clinically  significant laboratory abnormalities , will be collected in the 
site’s source document,  and reported on the AE case report form (CRF). Documentation of the serious 
event will be reported on the Serious Adverse Event (SAE) CRF and submitted to the Sponsor  within 24 
hours of awareness.  
AEs will be identified using the  FDA Guidance for Industry Toxicity Grading Scale for Healthy Adult and 
Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. The following information regarding each adverse event will be recorded:  
•Assessment period
•Severity Grade (0 -4)
•Attribution to study agent (relatedness)
•Date AE occurred
•Date AE resolved
•Whether or not the event was reported as an SAE
•Whether or not the participant dropped due to the event
•Action taken with study agent
•Outcome of the event
•Additional investigator c omments
AEs will be summarized by study group  and system organ class . Tables will include summaries of all AEs, 
all SAEs, all BIO 300 Oral Powd er related AEs, all BIO 300  Oral Powder related SAEs, all Grade 3 or 4 AEs, 
and all AEs leading to death or study discontinuation.  
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
31 9.4.5  BASELINE DESCRIPTIVE STATISTICS  
Baseline characteristics, such as subject  age, vital signs, laboratory results, and BMI  will be compared 
between the dosing cohorts  using descriptive statistics. ANOVA analysis will be used to compare each 
parameter between the study  cohorts  at baseline.  
9.4.6  PLANNED INTERIM ANALYSES  
Following the 2000 mg single ascending dose cohort, safety and PK analysis will be completed to 
determine the dose for the final cohort of the single ascending dose study.  
9.4.7  SUB -GROUP ANALYSES  
No sub -group analysis is planned.  
9.4.8  TABULATION OF INDIVIDUAL PARTICIPANT  DATA 
All individual participant data will be listed by measure and timepoint . 
9.4.9  EXPLORATORY ANALYSES  
There are no exploratory analyses planned for this study.  
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS 
10.1 REGULATORY, ETHICAL , AND S TUDY OVERSIGHT CONSIDERATIONS  
10.1.1 INFORMED CONSENT PROCESS  
10.1.1.1  CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANTS 
Consent forms describing in detail the study intervention , study procedures, and risks are given to the 
participant  and written documentation of informed consent is required prior to starting 
intervention/administering study intervention.   The informed  consent form (ICF) is  submitted with this 
protocol .  
10.1.1.2  CONSEN T PROCEDURES AND DOCUMENTATION  
The environment where the process of consent is conducted will be private, confidential, and safe in order to facilitate a constructive dialogue between the prospective subject and the person(s) involved in obtaining consent.  All prospective subjects must have the cognitive ability to provide legally effective 
informed consent. Individuals who do not have such ability (i.e., decisionally impaired persons) can only 
be enrolled in research through consent of their legally authorized representative (LAR). If there is any 
concern about an individual’s cognitive ability an appropriate assessment should be performed by a qualified individual.  
The informed consent will be presented and discussed with the prospective subject in a seque ntial 
manner utilizing the approved ICF as a guide. The presentation should be structured to facilitate a dialogue with reinforcement and elaboration of important information (e.g., the risks of the research). The person(s) involved in obtaining the subjec t’s consent will constantly evaluate whether the process is 
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
32 achieving the goal which is obtainment of legally effective informed consent from the subject. In 
addition to paying attention to general signs of information receptivity, the person obtaining con sent 
may ask open -ended questions in order to identify points of confusion which require clarification.  
A delayed consent procedure will be used in order to afford the subject the opportunity to discuss 
participation in the research with family, friends, c ounselors, or other confidants before they sign the 
ICF. If the individual is uncomfortable or anxious about participating in the research, they will be 
instructed to take the ICF home for further review and consideration before deciding whether or not to participate in the research.  
The informed consent process will be documented by personnel qualified to attest the that the subject has provided legally effective informed consent. The individual documenting the process and the consenting subject will sign and date the ICF and indicate the time at which the ICF was signed. It is unacceptable for the person documenting consent to sign the ICF in advance of obtaining the subject’s signature.  
The informed consent document must be reviewed and approved by the I RB, any changes to the 
informed consent must be submitted to the IRB for approval prior to initiation.   
10.1.2 STUDY DISCONTINUATION AND CLOSURE  
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause.  Written n otification, documenting the reason for study suspension or termination, will be 
provided by the suspending,  or terminating party to study participants, Principal I nvestigator, funding 
agency, the Investigational New Drug ( IND) Sponsor  and regulatory authorities.  If the study is 
prematurely terminated or suspended, the Principal I nvestigator (PI ) will promptly inform study 
participants, the Instituti onal Review Board ( IRB), and Sponsor  and will provide the reason(s) for the 
termination  or suspension.  Study participants will be contacted, as applicable, and be informed of 
changes to study visit schedule.  
 Circumstances that may warrant termination or suspension include, but are not limited to:  
•Determination of unexpected, significant, o r unacceptable risk to participants
•Demonstration of efficacy that would warrant stopping
•Insufficient compliance to protocol requirements
•Data that are not sufficiently complete and/or evaluable
•Determination that  the primary endpoint has been met
•Dete rmination of futility
Study may resume once concerns about safety, protocol compliance, and data quality are addressed, 
and satisfy the Sponsor , IRB and/or Food and Drug Administration ( FDA). 
10.1.3 CONFIDENTIALITY  AND PRIVACY   
In order to maintain subject confidentiality, a subject number and initials will identify all study subjects on CRFs and other documentation submitted to the Sponsor.   
Participant  confidentiality  and privacy is strictly held in trust by the Principal Investigator, their staff, and 
the Sponsor (s) and their intervention s. This confidentiality is extended to cover all aspects of  the clinical 
information relating to participants. Therefore, the study protocol, doc umentation, data, and all other 
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
34 10.1.6 SAFETY OVERSIGHT  
Safety oversight will be the responsibility  of the Principal Investigator  and the Medical Monitor.  
10.1.7 CLINICAL MONITORING  
Site monitoring will be  conducted  to ensure that the rights and well -being of trial participants  are 
protected, that the reported trial data are accurate, complete, and verifiable, and that the conduct of 
the trial is in compliance with the currently approved protocol/amendment(s), with IC H GCP, and 
with applicable regulatory requirement(s).  
Sponsor  will monitor the progress of all clinical investigations being conducted under its IND based on 
the study specific Monitoring Plan, which shall be prepared by the Sponsor . If Sponsor  discovers that 
a participating investigator is not complying with the si gned agreement (Form FDA -1572), the general 
investigational plan, or other requirements the study Sponsor  shall promptly either secure 
compliance or discontinue the investigator’s participation in the investigation.  
The Sponsor  will review and evaluate th e evidence relating to the safety and effectiveness of the drug as 
it is obtained from the participating investigator. The notification process to the study Sponsor  begins 
with the completion and submission of the appropriate CRFs.  Investigators are required to report 
promptly to the Sponsor  any adverse events that may reasonably be regarded as caused by, or probably 
caused by, the drug. If the adverse event meets the serious adverse event criteria, the investigator is required to report the event to the Sp onsor  within 24 hours of discovery.  
Prompt review of the AE by the study Sponsor  will be completed to determine if the AE meets any of the 
criteria for an AE to be reported to the FDA, Investigators, and/or Institutional Review Boards (IRB).  
Should an AE be determined by the study Sponsor  to meet the criteria for a 7- or 15 -day reportable 
event, the medical monitor will be notified promptly.  The medical monitor will assist in writing the IND 
safety report with the study Sponsor . The Sponsor  will submit all  necessary reports to FDA regarding 
information relevant to the safety of the drug.  
The study Sponsor  will promptly investigate all safety information it receives.   Should the Sponsor , in 
consultation with the Medical Monitor,  determine that the investigational drug presents an 
unreasonable and significant risk to subjects , the study shall be discontinued. In this case, the study 
Sponsor  will notify the FDA, all institutional review boards, and all investigators who have at any  time 
participated in the investigation of the discontinuance and assure the disposition of all stocks of the 
drug outstanding and furnish FDA with a full report of the Sponsor ’s actions.   
10.1.8 QUALITY ASSURANCE AND QUALITY CONTROL  
The clinical site will perf o
rm internal quality management of study conduct, data and biological 
specimen  collection, documentation,  and completion  per its Standard Operating Procedures (SOPs) .  
Quality control ( QC) procedures will be implemented beginning with the data entry system and data QC 
checks that will be run on the database will be generated. Any missing data or data anomalies will be communicated to the site(s) for clarification/resolution.  
Following writt en SOPs , the monitor (s) will verify that the clinical trial is conducted and data are 
generated  and biological specimens are collected , documented (recorded), and reported in compliance 
with the protocol, International Conference on Harmonisation Good Clin ical Practice (ICH GCP), and 
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
35 applicable regulatory requirements (e.g., Good Laboratory Practices ( GLP), Good Manufacturing 
Practices ( GMP )).  
The investigational site will provide direct access to all trial related sites, source data/documents, and 
reports  for the purpose of monitoring and auditing by the Sponsor , and inspection by local and 
regulatory authorities  as appropriate  and necessary.  
10.1.9 DATA  HANDLING  AND  RECORD  KEEPING  
10.1.9.1  DATA COLLECTION AND  MANAGEMENT RESPONSIBILITIES  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the Principal Investigator. The Principal Investigator is responsible for ensuring the accuracy, completeness, 
legibility, and timeliness of the data rep orted . 
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data.   
Hardcopies of the study visit worksheets  will be provided for use as source document  worksheets for 
recording data for each participant e nrolled in the study .  Data re cord ed in the electronic case report 
form ( eCRF ) derived from source documents should be consistent with the data recorded on the source 
documents .  
Clinical data (including a dverse events ( AEs), concomitant medications, and expected adverse reactions 
data) and clinical laboratory data will be entered into a study specific data capture system, a 21 CFR Part 
11-compliant data capture system utilized by the Sponsor . The data system includes password
protection and internal quality checks, such as automatic range checks, to identify data that appear
inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the source
documents.
10.1.9.2  STUDY RECORDS RETENTION  
Study document s should be retained for a minimum of 2 years after the last approval of a marketing 
application in an  International Conference on Harm onisation ( ICH) region and until there are no pending 
or contemplated marketing applications in an ICH region or  until at  least 2 years have elapsed since the 
formal discontinuation of clinical development of the study intervention . These documents should be 
retained for a longer period, however, if required by local regulations. No records will be destroyed without the writ ten consent of the Sponsor , if applicable. It is the responsibility of the Sponsor  to inform 
the investigator when these documents no longer need to be retained.  
10.1.10  PROTOCOL DEVIATIONS  
A protocol deviation is any noncompliance with the clinical trial protoc ol, International Conference on 
Harmonisation Good Clinical Practice ( ICH GCP) , or Manual of Procedures ( MOP ) requirements. The  
noncompliance may be either on the part of the participant , the investigator, or the study site staff. As a 
result of deviations, corrective actions are to be developed by the site and implemented promptly.  
These practices are consistent with ICH GCP : 
•4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3
•5.1 Quality Assurance and Quality Control, section 5.1.1
•5.20 Noncompliance, sections 5.20.1, and 5.20.2.
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
36 Compliance with the study protocol and all study procedures will be assessed during each  monitoring 
visit.  A protocol deviation for this study is defined as any departure from the protocol whether pre -
approved by the Sponsor  or unplanned. Protocol deviations may be identified during monitoring visits or 
by the site either in anticipation of a deviation or upon discovery. The research site should complete a 
Protocol Deviation CRF and submit it to the Sponsor  after review and signature by the investigator.  
Protocol deviations must be sent to the reviewing  Institutional Review Board (IRB)  per their policies. The 
site investigator is responsible for k nowing and adhering to the  reviewing IRB requirements. Further 
details about the handling of protocol deviations will be included in the MOP.  
As specified in the Study Monitoring Plan, the Sponsor  will review protocol deviations by site and overall 
to determine if there are any trends identified that may affect subject  safety, data integrity and the 
impact on analysis and to determine if any actions need to be taken prevent continued deviations.   
10.1.11  PUBLICATION AND DATA SHARING POLICY  
Publication of clinical trial results will be consistent with the Sponsor ’s Publication Policy. The first 
publication in journal, or presentation at a congress, will be based on the consolidated data, analyzed as 
stipula ted by the protocol and agreed upon by investigators.  
The Sponsor  intends  to share all applicable data collected as part of this project with the DoD and the 
general scientific community. The data will be made as widely and freely available as possible  through 
presentation  at scientific conferences and  publication of primary data in a peer- reviewed journal.  
10.1.12  CONFLICT OF  INTEREST  POLICY  
Any actual conflict of interest of persons who have a role in the design, conduct, analysis, publication, or 
any aspect of this trial will be disclosed and managed . Furthermore, persons who have a perceived 
conflict of interest will be required to have such conflicts managed in a way that is appropriate to their 
participation in the design and conduct of this t rial.   
10.2 ABBREVIATIONS  
AE Adverse Event  
ALP Alkaline Phosphatase  
ALT Alanine Transaminase  
ANCOVA  Analysis of Covariance  
ANOVA Analysis of Variance  
ASD Amorphous Spray Dried Dispersion  
AST Aspartate Aminotransferase  
AUC  Area -Under -The-Curve  
β-HCG  Human Chorionic Gonadotropin  
BMI Body mass Index  
BUN Blood Urea Nitrogen  
CBC Complete Blood Count  
CC Cubic Centimeter  
  
CFR Code of Federal Regulations  
Cmax Maximum (Peak) Concentration  
CONSORT  Consolidated Standards of Reporting Trials  

Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
Confidential Information of Humanetics Corporation   37 
 COVID -19  Coronavirus Disease 2019  
CRF    Case Report Form  
CTCAE    Common Terminology Criteria for Adverse Events  
CTPA     Computed Tomography Pulmonary Angiogram  
DEG     Differentially Expressed Gene  
DLT    Dose Limiting Toxicity  
DVT    Deep Vein Thrombosis  
ECG    Electrocardiogram  
eCRF     Electronic Case Report Form  
ERβ    Estrogen Receptor Beta  
FDA    US Food and Drug Administration  
FPKM     F ragments Per Kilobase Million  
   
GCP    Good Clinical Practice  
GLP    Good Laboratory Practice  
GMP    Good Manufacturing Practice  
g     Gram  
HDL    High- Density Lipoprotein  
HEENT    Head, Eyes, Ears, Nose and Throat   
H/Hr    Hours  
IB     Investigator’s Brochure  
ICF     Informed Consent Form  
ICH    International Conference on Harmonisation  
    
     
      
IND    Investigational New Drug Application  
INR    International Normalized Ratio Based On PTT  
IRB    Institutional Review Board 
ITT     Intention -to-Treat  
Kg     Kilogram  
LAR    Legally Authorized Representative  
LBBB    Left Bundle Branch Block  
LDPE     Low-Density Polyethylene  
LLDPE     L inear Low-Density Polyethylene  
M2     Square Meters  
MedDRA    Medical Dictionary fo r R egulatory Activities  
M/F     Male/Female  
mg     Milligram  
min    Minute  
mL     Milliliter  
msec     Millisecond  
MOP     Manual of Procedures  
MTD     Maximum Tolerated Dose  
N     Number  
NCT    National Clinical Trial  

Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
38 NF-κB  Nuclear Factor Kappa Light -Chain -Enhancer of Activated B Cells  
  
NIH National Institutes of Health  
NF National Formulary and Drug Standards Laboratory  
NYHA  New York Heart Association  
OHRP  Office for Human Research Protections  
oz Fluid Ounce  
PD  Pharmacodynamics  
PI Principal Investigator  
PK Pharmacokinetics  
PTT Prothrombin Time  
PVC Premature Ventricular Contractions  
QC  Quality Control  
QTc Corrected QT Interval  
QTcF  QTc with Fridericia’s Correction  
RBC Red Blood Cells  
RNA  Ribonucleic Acid  
SAD Single Ascending Dose  
SAE Serious Adverse Event  
SD Standard Deviation  
SoA Schedule of Assessments  
SOP Standard Operating Procedure  
T1/2  Half- life 
TBD To Be Determined  
Tmax Time to Reach C max 
  
  
UP  Unanticipated Problems  
USP United States Pharmacopeia  
VTE Venous Thromboembolism  
w Weight  
WBC White Blood Cells  
Yrs  Years  
10.3 PROTOCOL  AMENDMENT  HISTORY  
The table below is intended to capture changes of IRB -approved versions of the protocol, including a 
description of the change and rationale. A Summary of Changes table for the current amendment is 
located in the Protocol Title Page.  
Version  Date  Description of Change  Brief Rationale  
0.5 17Sep2020  Initial Release  Initial Release  
1.0 16Nov2020  Changed the biomarkers of interest , 
time period and frequency of AE 
reporting and reporting of pregnancy Revised t o include acute 
radiation syndrome relevant 
biomarkers, provide consistency 
with the Schedule Activities , 

Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
39 and remove unnecessary 
language.  
2.0 16Mar2021  Change d the blood draw times for 
PD (biomarkers) on day 6 of the 
multiple single dose study 
Added a pre
gnancy test to day 1 of 
the Multiple Single Dose Study 
Cohort The original blood draw times 
were based on the predicted 
Cmax of BIO 300 Oral Powder from animal studies. The 
updated blood draw times are 
based on the actual Cmax from 
all 4 cohorts in the SAD study 
conducted under this protocol.  
Pregnancy test added to day 1 of the Multiple Single Dose Study 
Cohort to align with inclusion 
criteria requiring a negative pregnancy test within 72 hours 
of day 1.  
Phase 1 BIO 300 Oral Powder  Version 3.0 
Protocol CL0106-01 07 June 2021  
40 11 REFERENCES 
1.Hamalainen M, Nieminen R, Vuorela P, Heinonen M, Moilanen E. Anti -inflammatory effects of flavonoids:
genistein, kaempferol, quercetin, and daidzein inhibit STAT -1 and  NF-kappaB activations, whereas flavone,
isorhamnetin, naringenin, and pelargonidin inhibit only NF -kappaB activation along with their inhibitory effect on
iNOS expression and NO production in activated macrophages. Mediators of inflammation 2007;2007:45673.
2.Pons DG, Vilanova -Llompart J, Gaya- Bover A, et al. The phytoestrogen genistein affects inflammatory -related
genes expression depending on the ERalpha/ERbeta ratio in breast cancer cells. Int J Food Sci Nutr 2019:1 -9.
3.Liu J, Viswanadhapalli S, Garcia L, et al. Therapeutic utility of natural estrogen receptor beta agonists on ovarian
cancer. Oncotarget 2017;8:50002- 14.
4.Liu T, Zhang L, Joo D, Sun SC. NF -kappaB signaling in inflammation. Signal Transduct Target Ther 2017;2.
5.Chen Y, Xiao CQ, He YJ , et al. Genistein alters caffeine exposure in healthy female volunteers. European journal
of clinical pharmacology 2011;67:347- 53.
12 APPEN DICES 
APPENDIX 1: SOY RICH F OODS  
The following is a list of soy rich foods that study participants should be counseled to avoid while participating in 
the study:  
• Edamame
• Meat Alternatives containing soy protein or tofu, e.g.no meat hot dogs
• Miso
• Natto
• Nutritional drinks and bars with added s oy protein
• Soymilk
• Soy cheese
• Soy ice cream
• Soy yogurt
• Soy Nuts
• Tempeh
• Textured Soy Protein
• Tofu
• Whole Soybeans
Use to the following links for additional information on soy rich foods:  
http://www.ucsfhealth.org/education/a_guide_to_foods_rich_in_s oy/ 
http://www.ars.usda.gov/SP2UserFiles/Place/80400525/Data/isoflav/Isoflav_R2.pdf  
 STATISTICAL ANALYSIS PLAN  
Study Title:  A Phase 1 Dose Escalation Trial Evaluating the Safety and 
Pharmacokinetic Profile of BIO 300 Oral Powder in Healthy 
Volunteers 
Protocol  Number:  CL010 6-01 
  
Investigation al Agent:  BIO 300  Oral Powder  
Phase of Development:  Phase 1 
Sponsor:  Humanetics Corporation  
7650 Edinborough Way, Suite 620  
Edina, M innesota  55435 
Date of SAP:  December  28, 2020  (version 1.0 ) 
Amendment History:  Original Version  

CL0106-01  Statistical Analysis Plan  December 28 , 2020 
 
 1  
Table of Contents  
1. INTRODUCTION  ............................................................................................................................ 2  
2. STUDY OBJECTIVES........................................................................................................................ 2  
2.1. PRIMARY OBJECTIVES  ...................................................................................................................... 2  
2.2 SECONDARY OBJECTIVES  ...................................................................................................................... 2  
3. STUDY ENDPOINTS  ........................................................................................................................ 2  
3.1. PRIMARY ENDPOINT  ....................................................................................................................... 2  
3.2. SECONDARY ENDPOINT  .................................................................................................................... 3  
4. SAMPLE SIZE  ................................................................................................................................. 3  
5. ANALYSIS POPULATIONS ............................................................................................................... 3  
5.1. INTENTION -TO-TREAT ANALYSIS DATASET  ........................................................................................... 3  
5.2. SAFETY ANALYSIS DATASET  .............................................................................................................. 3  
5.3. PHARMACOKINETIC (PK)  POPULATION  ............................................................................................... 3  
5.4. PHARMACODYNAMICS (PD)  POPULATION  ........................................................................................... 3  
6. SAFETY MONITORING COMMITTEE ............................................................................................... 3  
7. STATISTICAL METHODS  ................................................................................................................. 4  
7.1. DEFINITIONS  ................................................................................................................................. 4  
7.2. MISSING VALUE S ........................................................................................................................... 4  
7.3. VISIT WINDOWS  ............................................................................................................................ 4  
7.4. INTERIM ANALYSIS  ......................................................................................................................... 5  
7.5. SIGNIFICANCE LEVEL  ........................................................................................................................ 5  
8. GENERAL DATA ANALYSE S ............................................................................................................ 5  
8.1. SUBJECT DISPOSITION  ..................................................................................................................... 5  
8.2. PROTOCOL DEVIATIONS  ................................................................................................................... 5  
8.3. BASELINE AND DEMOGRAPHIC CHARACTERISTICS  .................................................................................. 5  
9. ENDPOINT ANALYSES .................................................................................................................... 5  
9.1. ANALYSIS FOR SAFETY ENDPOINTS  ..................................................................................................... 5  
9.2. ANALYSIS FOR THE PHARMACOKINETIC PROFILE  .................................................................................... 5  
9.3. ANALYSIS FOR BLOOD -BASED BIOMARKERS  ......................................................................................... 6  
10. SAFETY ANALYSES ....................................................................................................................... 6  
10.1.  EXPOSURE TO BIO  300  ORAL POWDER  ............................................................................................. 6  
10.2.  ADVERSE EVENTS  ......................................................................................................................... 6  
10.3.  CLINICAL LABORATORY TEST RESULTS  ............................................................................................... 7  
10.4.  VITAL SIGNS ................................................................................................................................ 7  
10.5.  ELECTROCARDIOGRAMS  ................................................................................................................. 7  
11. SYMBOLS AND ABBREVIA TIONS  .................................................................................................. 8  
 
  
CL0106-01  Statistical Analysis Plan  December 28 , 2020 
 
 2 1. Introduction 
Protocol Title:  A Phase 1 Dose Escalation Trial Evaluating the Safety and Pharmacokinetic Profile of BIO 
300 Oral Powder in Healthy Volunteers  
Protocol  Number:  CL010 6-01 
 
Investigational  Agent:  BIO 300 Oral Powder  
Phase of Development:  Phase 1 
Sponsor:  Humanetics Corporation  
Design:  Open label, single site phase 1 study in healthy volunteers who are equally distributed by sex. The 
study will include a single ascending dose (SAD) study in four cohorts and will be followed by a six -day 
multiple single dose (MSD) study at either the highest dose or the maximum tolerated dose. There are no 
planned stratifications or sub -studies. 
This Statistical Analysis Plan (SAP) details the planned methods for summarizing data collected in the 
clinical study conducted under  Humanetics Corporation  protocol CL0106-01. The current study protocol 
is identified as  version 1.0 dated 16-Nov -2020. 
Future protocol amendments (if any) will be reviewed to assess whether the changes necessitate 
modification of this SAP.  
Since the study protocol is a companion document to this SAP, aspects in the protocol unrelated to 
statistical issues (e.g., patient eligibility criteria  and detailed BIO 300 Oral Powder information) are not 
repeated here . 
2. Study Objectives  
2.1. Primary Objectives 
• Determine the overall adverse event and pharmacokinetic ( PK) profiles of single ascending 
doses of BIO 300 Oral Powder in healthy volunteers  
• Determine the overall adverse event and PK profile of multiple doses of BIO 300 Oral Powder in 
healthy volunteers  
2.2 Secondary Objectives  
• Determine the effects of single and multiple doses of BIO 300 Oral Powder on blood -based 
biomarkers  
• Use a combination of the PK and pharmacodynamic ( PD) profiles from the single and multiple 
doses of BIO 300 Oral powder to identify the putative BIO 300 Oral Powder human efficacious 
dose  
3. Study Endpoints  
3.1. Primary Endpoint  
• Evaluate the safety and pharmacokinetics of BIO 300 Oral Powder in Healthy Volunteers  

CL0106-01  Statistical Analysis Plan  December 28 , 2020 
 
 3 3.2. Secondary Endpoint  
• Characterize the expression of blood-based biomarkers  
4. Sample Size 
• 6 subjects/cohort (3M/3F) will be recruited for the single ascending dose study, and at least 6 
(3M/3F) subjects/cohort will complete all aspects of the study.  2 additio nal subjects (1M/1F), will 
be screened, consented and available as backups for each cohort.  
• 10 (5M/5F) subjects will be recruited for the multiple single dose study, and at least 8 (4M/4F) 
subjects will complete all aspects of the study. 4 additional subjects (2M/2F) will be screened, 
consented and available as backups.  
• In total, at least 32 healthy volunteers who will complete all aspects of the trial.  
The single ascending dose study consists of 4 cohorts, each with at least 6 subjects completing all aspec ts 
of the study, split evenly to include at least 3 females and 3 males. As such, 12 females and 12 males will participate for a total of 24 subjects. The multiple single dose study will include at least 8 subjects 
completing all aspects of the study, spli t evenly to include at least 4 females and 4 males. This is a sufficient 
number of subjects in each study to characterize the PK and PD of BIO 300 Oral Powder and to identify dose limiting toxicities (DLTs ).   
5. Analysis  Populations  
5.1. Intention- to-Treat Analys is Dataset  
The Intention -to-Treat ( ITT) analysis dataset will include all study participants  
5.2. Safety  Analysis Dataset  
All study participants  who receive at least one dose of BIO 300 Oral Powder . This analysis set will be used 
to summarize all safety endpoin ts. 
5.3. Pharmacokinetic (PK) Population 
The PK Population will include all subjects who receive at least 1 dose of BIO 300  Oral Powder  and have 
sufficient, valid serum samples to estimate key parameters for at least 1 of the days of sampling. PK 
summaries will be based on the PK population.  
5.4. Pharmacodynamics (PD) Population  
The PD Population will include all subjects who receive at least 1 dose of BIO 300 Oral Powder and have sufficient, valid serum samples to estimate key parameters for at least 1 of the days of sampling. PD 
summaries will be based on the PD population.  
6. Safety Monitoring Committee  
A Safety Monitoring Committee (SMC) will review safety and PK data  (when available)  during the conduct 
of the study. After each cohort in the SAD study, the SMC will make decisions on  proceeding with dose 
escalation, adding additional subjects to the current c ohort , and  possible dose adjustments . The SMC  may  
also recommend stopping the study, suspending enrollment or significant changes to the dosing regimen  
and/or enr ollment if warranted by safety  data . The SMC will immediately communicate this 
recommendation to Humanetics for review and determination of a final decision. SMC  data reviews are 
CL0106-01  Statistical Analysis Plan  December 28 , 2020 
 
 4 not considered interim analyses and do not necessitate adjusting of the alpha  level for multiple statistical 
hypothesis tests. 
7. Statistical Methods  
Unless stated otherwise, the term “descriptive statistics” refers to the number of subjects (n), mean, 
median, standard deviation (STD), minimum (min), and maximum (max) and standard errors/confidence 
intervals for continuous response variables and distribution tables or histograms for discrete response 
variables. Min and max values will be rounded to the precision of the original value, means and medians 
will be rounded to 1 decimal place greater than the precision of the original value, and STDs will be 
rounded to 2 decimal places greater than the precision of the original value. Percentages will be rounded 
to the nearest whole number (zeros are not displayed) with values of “< 1%” and “ > 99%” shown as 
necessary for values falling near the boundaries.  
The computed change from baseline will be calculated for all measured variables and expressed as the mean change from baseline + STD of the change from baseline. Analysis of covariance will be used to 
compare dosage groups on “change from baseline” measures (with baseline measurement considered as 
an adjustment covariate).   
Unless otherwise note, all data collected during the study will be included in data listings and will be sorted 
by study  cohort , subject number and then by visit for each subject number.  
7.1. Definitions  
• Baseline is synonymous with screening, and the baseline value  (or baseline result) is that 
measured  during the screening visit prior to the first administration of BIO 300 Oral Powder. 
• Day 1 is the first day of dosing with BIO 300 Oral Powder. 
• Estimand is the estimated value for a parameter or, alternatively, a formula and/or description for how a parameter is estimated.  
• Proportional months, defined for durations of time reported  in months, are given by the formula  
months =12
365.25×days  
• Shift table is a two -way frequency table pairing baseline value with the most extreme post -
baseline result.  
7.2. Missing Values 
Given the small sample size, descriptive statistics and other analyses will be completed without replacing 
or imputing missing values. 
7.3. Visit Windows  
The study protocol defines a visit schedule based on the number of days since the first dose of  BIO 300 
Oral Powder  (Day 1 ). All study participants will be instructed on when they need to return to the clinic in 
order to meet all scheduled assessments. Assessments outside of the scheduled visit  window  will be 
analyzed (by visit according to the clinical database) as if they occur within the visit window; that is, no 
data will be excluded if it is measured  outside the visit window.  
CL0106-01  Statistical Analysis Plan  December 28 , 2020 
 
 5 7.4. Interim Analysis  
Following the third SAD  cohort , PK analysis will be completed for all subjects  (cohorts 1 -3) and analyzed 
along with all safety data t o determine the dose for the final cohort of the SAD study. No other interim 
analyses are planned. SMC data reviews are not considered interim analyses (see Section 6 ). 
7.5. Significance level  
An independent statistician using standard statistical techniques will determine statistically significant 
differences in the trial measurement data at the nominal 0.05 level of significance.      
8. General Data Analyses  
8.1. Subject  Disposition  
The numbers of subjects  who were enrolled and  dosed with BIO 300 Oral Powder will be summarized by 
frequency counts. R easons for discontinu ing BIO 300 Oral Powder and study completion status will be 
summarized as categorical variable s (number and percentage of subjects  in each category). Relevant data 
supporting these summaries will be listed by subject . 
8.2. Protocol Deviations  
Study inclusion/exclusion criteria violations and protocol deviations recorded in the clinical database, if any, will be summarized as categorical variables (number and percentage of subjects  in each category). 
Relevant data supporting this summary will be listed by subject.  
8.3. Baseline and Demographic Characteristics 
Demographic and baseline characteristic data will be summarized with descriptive statistics for age, 
gender, race, ethnicity, height, weight, BMI, vital signs and laboratory results . ANOVA analysis will be used 
to compare each parameter between the study cohorts at baseline.  
9. Endpoint Analyses  
All observations available in the study database will be included  in endpoint analysis regardless of 
subjects ’ aggregate exposure to BIO 300 Oral Powder , use of concomitant medications, or violations of 
the protocol . Relevant data supporting efficacy analy ses will be listed by subject .  
9.1. Analysis  for Safety Endpoints  
Safety data will include adverse events ( AEs), safety laboratory (CBC/hematology, serum chemistry and 
urinalysis), pregnancy (if applicable), drug and alcohol tests test, physical exam, ECG, and vital signs. The 
proportion of subjects experiencing adverse events, serious adverse events, and DLTs  will be 
summarized for each dosing cohort. See Section 10  for more information on safety analysis.  
9.2. Analysis for the Pharmacokinetic Profile  
PK parameters will be estimated using nominal sampling times relative to each dose administration and 
nominal doses unless otherwise specified. Serum concentration values obtained at the predose time point 
will be used to estimate the concentration at time zero  (baseline) .  Concentration values reported as not 
quantifiable (BLQ, <1.0 ng/mL) will be assigned a value of zero.    
The area under the concentration vs. time curve (AUC) will be calculated using the linear trapezoidal method with linear interpolation. The AUC will not be calculated for PK profiles with less than 3 
quantifiable concentrations of BIO 300 Oral Powder at separate time points. When practical, the terminal 
CL0106-01  Statistical Analysis Plan  December 28 , 2020 
 
 6 elimination phase of each concentration versus time curve will be identified using at least three observed 
concentration values after Cmax, but not including Cmax. The slope of the terminal elimination phase will 
be determined using log linear regression on the unweighted concentration data. Parameters relying on 
the determination of the terminal elimination phase will not be reported if the coefficient of 
determination is less than 0.800, or if the extrapolation of the AUC to infinity represented more than 20% 
of the total area. The parameters Tmax, Cmax, AUC(0-t), AUC (0-inf) and T1/2 will be reported for each 
SAD cohort and for the MSD cohort on after the Day 6 dose of BIO 300 Oral Powder.  
9.3. Analysis for Blood -Based Biomarkers  
Blood -based biomarkers will be identified by extracting RNA from whole blood samples and performing 
transcriptome analysis to determine differential gene expression.  Transcriptome analysis will  be 
conducted  by paired -end RNA sequencing. After investigating the quality of the raw sequencing data, 
sequence reads will be  trimmed to remove possible adapter sequences and nucleotides with poor quality 
using Trimmomatic v.0.36. The trimmed reads w ill be  mapped to the Homo sapiens reference gen ome 
available on ENSEMBL using the STAR aligner v.2.5.2b. The STAR aligner is a splice aligner that detects 
splice junctions and incorporates them to help align the entire read sequences. Binary Alignment Map 
(BAM ) files will be  generated as a result of this step. Unique gene hit counts w ill be  calculated by using 
feature c ounts from the Subread package v.1.5.2. Only unique reads that fell within exon regions w ill be  
counted.  
After extraction of gene hit counts, the gene hit counts table w ill be  used for do wnstream differential 
expression analysis. Using DESeq2, a comparison of gene expression between the groups of samples w ill 
be performed. The Wald test will be  used to generate p -values and Log2 fold changes. Genes with adjusted 
p-values < 0.05 and absolut e log2 fold changes > 1 w ill be  called as differentially expressed genes for each 
comparison. A gene ontology analysis w ill be  performed on the statistically significant set of genes by 
implementing the software GeneSCF. The goa _human GO list w ill be used to cluster the set of genes based 
on their biological process and determine their statistical significance. A principal component analysis 
(PCA) will be  performed using the "plotPCA" function within the DESeq2 R package. Th is plot will show 
the samples in a 2D plane spanned by their first two principal components. The top 500 genes, selected 
by highest row variance, w ill be  used to generate the plot.  
10. Safety  Analyses  
Summaries of safety endpoints will include data collected from the safety analysis dataset . Relevant data 
supporting safety analyses will be listed by subject. 
10.1. Exposure to BIO 300 Oral Powder  
For the SAD study , safety data will also be listed by cohort in order to analyze safety endpoints by dose 
level. For the MSD study, t he number of BIO 300 Oral Powder  doses  will be calculated and summarized 
by the mean, standard deviation, median, minimum and maximum values.  
10.2. Adverse Events  
The FDA guidance entitled “ Toxicity  Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled 
in Preventive Vaccine Clinical Trials” will be used to grade all AEs. All reported terms and descriptions for 
AEs will be coded using this FDA guidance  and summarized with frequencies and percentages by 
treatment group, system organ classification (SOC) and preferred term.  
CL0106-01  Statistical Analysis Plan  December 28 , 2020 
 
 7 All AEs will be included in comprehensive and cohort separated data listings. Additionally, AE summaries 
will be provided for the following: 
• DLT 
• Serious AEs ( SAEs ) 
• All Grade 3 or 4 AEs  
• AEs leading to discontinuation from the study  
• AEs by severity using Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled 
in Preventive Vaccine Clinical Trials  grades 
• AEs with 10% or higher incidence rates  
For all AE summaries, events will be counted only once per subject by primary SOC and preferred term. 
When an AE occurs more than once for a subject, the maximum severity and causality will be used.  
Partial start and end dates for adverse events will be replaced by calendar dates that maximize the 
duration of the adverse event. The following steps wi ll be followed.  
For a partial start date:  
1. Replace a missing month with January  
2. Replace a missing calendar day with the first of the month  
For a partial end date:  
1. Replace a missing month with December  
2. Replace a missing calendar day with the last day of the month  
An end date will not be estimated for adverse events marked continuing at the end of the study . 
10.3. Clinical Laboratory Test Results 
Subject  minimum and maximum post -baseline laboratory values (and changes from baseline) for analytes 
measured  on a continuous scale will be summarized by the mean, standard deviation, median, minimum 
and maximum values. The same statistics will be calculated to summarize laboratory test results by visit.  
Ordinal categorical test results  with a corresponding  Toxic ity Grading Scale for Healthy Adult and 
Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials  severity scale  will be summarized 
using shift tables.  
Urinalysis tests such as specific gravity and pH were collected only to assess a subjects’  eligibility to 
participate in the study. No analyses are planned for urinalysis test results.  
10.4. Vital Signs  
Subject  minimum and maximum post -baseline systolic and diastolic blood pressures, respiratory rate, 
pulse rate, temperature and body weight  (and changes from baseline) will be summarized by the mean, 
standard deviation, median, minimum and maximum values.  The same statistics will be calculated to 
summarize vital signs by visit.  
10.5. Electrocardiograms  
ECG QTc measurements will be summarized with descriptive  statistics and time point with respect to BIO 
300 Oral Powder administration. All ECG data will be displayed in a data listing.  
CL0106-01  Statistical Analysis Plan  December 28 , 2020 
 
 8 11. Symbols and Abbreviations  
AE Adverse Event  
ANOVA  Analysis of Variance  
AUC  Area Under the Curve  
BAM  Binary Alignment Map  
BLQ Below the Limit of Quantitation  
BMI Body -Mass Index  
CBC Complete Blood Count  
Cmax  Maximum (Peak) Serum Concentration  
DLT Dose Limiting Toxicity  
ECG Electrocardiogram  
F Female  
FDA U.S. Food and Drug Administration  
ITT Intent to Treat  
Inf Infinity  
M Male  
Max  Maximum  
Min Minimum  
mL Milliliter  
MSD  Multiple Single Dose  
ng Nanogram  
PCA Principal component analysis  
PD Pharmacodynamics  
PK Pharmacokinetics  
QTc Corrected QT Interval  
RNA  Ribonucleic Acid  
SAD Single Ascending Dose  
SAE Serios Adverse Event  
SAP Statistical Analysis Plan  
SMC  Safety Monitoring Committee  
SOC System Organ Classification  
STD Standard Deviation  
t time  
T1/2 Half-Life 
Tmax  Time to Reach Maximum (Peak) Serum Concentration  
 